<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">88144</article-id><article-id pub-id-type="doi">10.7554/eLife.88144</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.88144.4</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Ligand bias underlies differential signaling of multiple FGFs via FGFR1</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-313288"><name><surname>Karl</surname><given-names>Kelly</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-313290"><name><surname>Del Piccolo</surname><given-names>Nuala</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5104-7322</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-313289"><name><surname>Light</surname><given-names>Taylor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-313291"><name><surname>Roy</surname><given-names>Tanaya</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0939-7158</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-313292"><name><surname>Deduja</surname><given-names>Pooja</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-313293"><name><surname>Ursachi</surname><given-names>Vlad-Constantin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-72094"><name><surname>Fafilek</surname><given-names>Bohumil</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3869-7937</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-68553"><name><surname>Krejci</surname><given-names>Pavel</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0618-9134</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-47939"><name><surname>Hristova</surname><given-names>Kalina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4274-4406</contrib-id><email>kh@jhu.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00za53h95</institution-id><institution>Department of Materials Science and Engineering, Institute for NanoBioTechnology, and Program in Molecular Biophysics, Johns Hopkins University</institution></institution-wrap><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02j46qs45</institution-id><institution>Department of Biology, Faculty of Medicine, Masaryk University</institution></institution-wrap><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032h9wv69</institution-id><institution>Institute of Animal Physiology and Genetics of the CAS</institution></institution-wrap><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/027v97282</institution-id><institution>International Clinical Research Center, St. Anne's University Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>03</day><month>04</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP88144</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-04-06"><day>06</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-04-04"><day>04</day><month>04</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.01.06.475273"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-06-06"><day>06</day><month>06</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88144.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-08-10"><day>10</day><month>08</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88144.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-10-16"><day>16</day><month>10</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88144.3"/></event></pub-history><permissions><copyright-statement>© 2023, Karl et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Karl et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-88144-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-88144-figures-v1.pdf"/><abstract><p>The differential signaling of multiple FGF ligands through a single fibroblast growth factor (FGF) receptor (FGFR) plays an important role in embryonic development. Here, we use quantitative biophysical tools to uncover the mechanism behind differences in FGFR1c signaling in response to FGF4, FGF8, and FGF9, a process which is relevant for limb bud outgrowth. We find that FGF8 preferentially induces FRS2 phosphorylation and extracellular matrix loss, while FGF4 and FGF9 preferentially induce FGFR1c phosphorylation and cell growth arrest. Thus, we demonstrate that FGF8 is a biased FGFR1c ligand, as compared to FGF4 and FGF9. Förster resonance energy transfer experiments reveal a correlation between biased signaling and the conformation of the FGFR1c transmembrane domain dimer. Our findings expand the mechanistic understanding of FGF signaling during development and bring the poorly understood concept of receptor tyrosine kinase ligand bias into the spotlight.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>signal transduction</kwd><kwd>FGFR</kwd><kwd>biased signaling</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>GM068619</award-id><principal-award-recipient><name><surname>Hristova</surname><given-names>Kalina</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>2106031</award-id><principal-award-recipient><name><surname>Hristova</surname><given-names>Kalina</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001824</institution-id><institution>Czech Science Foundation</institution></institution-wrap></funding-source><award-id>GA19-20123S</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001824</institution-id><institution>Czech Science Foundation</institution></institution-wrap></funding-source><award-id>GF21-26400K</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Ministry of Education, Youth and Sports of the Czech Republic</institution></institution-wrap></funding-source><award-id>INTER-ACTION LUAUS23295</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Grant Agency of Masaryk University</institution></institution-wrap></funding-source><award-id>MUNI/G/1771/2020</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>National Institute for Cancer Research</institution></institution-wrap></funding-source><award-id>LX22NPO5102</award-id><principal-award-recipient><name><surname>Krejci</surname><given-names>Pavel</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Agency for Healthcare Research of the Czech Republic</institution></institution-wrap></funding-source><award-id>NU21-06-00512</award-id><principal-award-recipient><name><surname>Fafilek</surname><given-names>Bohumil</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Fibroblast growth factor (FGF) ligands exhibit different preferences for signaling cascades triggered through FGFR1, a receptor which is critical for skeletal development, and these differences likely contribute to the amazing complexity of developmental processes.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Fibroblast growth factor receptors (FGFRs) belong to the family of receptor tyrosine kinases (RTKs), which signal via lateral dimerization in the plasma membrane to control cell growth, differentiation, motility, and metabolism (<xref ref-type="bibr" rid="bib46">Lemmon and Schlessinger, 2010</xref>; <xref ref-type="bibr" rid="bib77">Schlessinger, 2000</xref>; <xref ref-type="bibr" rid="bib63">Paul and Hristova, 2019</xref>). The four known FGFRs (FGFR1–4) are single-pass membrane receptors, with an N-terminal ligand-binding extracellular (EC) region composed of three Ig-like domains, a transmembrane (TM) domain, an intracellular (IC) region that contains a juxtamembrane (JM) domain, a kinase domain, and a cytoplasmic tail (<xref ref-type="bibr" rid="bib21">Goetz and Mohammadi, 2013</xref>). The cross-phosphorylation of tyrosines in the activation loop of the FGFRs in the ligand-bound dimers is known to stimulate catalytic activity, resulting in the phosphorylation of secondary IC tyrosines, which recruit cytoplasmic effector proteins (<xref ref-type="bibr" rid="bib15">Eswarakumar et al., 2005</xref>; <xref ref-type="bibr" rid="bib32">Karl and Hristova, 2021</xref>). These effector proteins, once phosphorylated by the FGFRs, trigger downstream signaling cascades that control cell behavior (<xref ref-type="bibr" rid="bib78">Schlessinger, 2004</xref>; <xref ref-type="bibr" rid="bib89">Tomlinson et al., 2009</xref>).</p><p>The FGFRs signal in response to EC ligands with a beta trefoil fold, called fibroblast growth factors (FGFs) (<xref ref-type="bibr" rid="bib61">Ornitz and Itoh, 2001</xref>). As many as 18 different FGF ligands are known to bind to and trigger distinct cellular responses through a total of seven variants of four FGFRs (FGFR1–4) (<xref ref-type="bibr" rid="bib60">Ornitz et al., 1996</xref>; <xref ref-type="bibr" rid="bib99">Zhang et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Buchtova et al., 2015</xref>). The diversity in FGF-FGFR interactions far exceeds that of other RTK systems, reflecting the morphogen role that FGF signaling plays in the development of many tissues and organs. FGFR1 is well known for its critically important role in the development of the skeletal system, and has been implicated in many cancers (<xref ref-type="bibr" rid="bib62">Passos-Bueno et al., 1998</xref>; <xref ref-type="bibr" rid="bib94">Wilkie, 2005</xref>; <xref ref-type="bibr" rid="bib93">White et al., 2005</xref>; <xref ref-type="bibr" rid="bib90">Turner et al., 2010</xref>; <xref ref-type="bibr" rid="bib81">Seo et al., 2014</xref>). One specific example of a developmental process controlled by FGFR1 is limb bud outgrowth (<xref ref-type="bibr" rid="bib52">Mariani and Martin, 2003</xref>; <xref ref-type="bibr" rid="bib88">Tabin and Wolpert, 2007</xref>). The limb bud forms early in the developing embryo and consists of mesenchymal cells sheathed in ectoderm. The process starts as the mesenchymal cells begin to proliferate until they create a bulge under the ectodermal cells above. This is followed by the formation of the apical ectodermal ridge (AER) by the cells from the ectoderm, which specifies the proximal-distal axis of the limb, ensuring limb outgrowth (<xref ref-type="bibr" rid="bib52">Mariani and Martin, 2003</xref>; <xref ref-type="bibr" rid="bib88">Tabin and Wolpert, 2007</xref>). These roles are carried out by several FGF ligands, including FGF4, FGF8, and FGF9, which are produced and secreted by the ectodermal cells in the AER and have similar spatiotemporal expressions. The ligands diffuse into the mesenchymal region adjacent to the AER, and act upon the mesenchymal cells which express only the ‘c’ variant of FGFR1 (FGFR1c). This leads to the activation of signaling pathways downstream of FGFR1c, promoting survival and proliferation of the mesenchymal cells.</p><p>Experiments involving genetic ablation of FGF4, FGF8, and FGF9 have led to distinct limb malformations (<xref ref-type="bibr" rid="bib53">Mariani et al., 2008</xref>). Thus, the actions of these ligands through FGFR1c are different, but the mechanism behind the differential response of FGFR1c to multiple ligands has not been investigated. More broadly, it is not known how a cell recognizes the identities of different FGF ligands, when bound to and signaling through the same FGFR. Here, we sought to investigate the molecular mechanism behind differences in FGFR1c signaling in response to FGF4, FGF8, and FGF9.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Differences in FGF-induced activation of the ERK pathway in cultured chondrocytes</title><p>To investigate whether FGF4, FGF8, and FGF9 induce differential signaling via FGFR1c (referred to as FGFR1 here), we used rat chondrosarcoma (RCS) chondrocytes, an immortal chondrocyte cell line used to model proliferating chondrocytes in the developing limb (<xref ref-type="bibr" rid="bib17">Fafilek et al., 2018</xref>). By western blot, the RCS cells express detectable amounts of both FGFR1 and FGFR2 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). While FGFR3 and FGFR4 cannot be detected by western blotting, transcripts for FGFR3 and FGFR4 can be found by qPCR. To create an RCS variant that expresses FGFR1 only, CRISPR/Cas9 was used to disrupt the endogenous FGFR2<italic>,</italic> FGFR3, and FGFR4 genes in RCS cells (<xref ref-type="bibr" rid="bib37">Kimura et al., 2021</xref>) to generate cells expressing only the endogenous FGFR1 (RCS<sup>Fgfr1</sup>). As a control, we used CRISPR/Cas9 to disrupt all endogenous <italic>FGFR</italic> genes in RCS cells (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; RCS Fgfr1–4 null). The RCS<sup>Fgfr1</sup> cells were treated with FGF4, FGF8, and FGF9 for up to 1 hr. The activation of the RAS-ERK MAP kinase pathway, which represents the major downstream signaling FGFR module, was monitored by western blot (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="supplementary-material" rid="fig1sdata5">Figure 1—source data 5</xref>). FGF4, FGF8, and FGF9 showed significant differences in FGFR1-mediated activation of ERK, with FGF4 inducing the strongest signal, compared to weaker signals detected in cells treated with FGF8 and FGF9. To investigate the dynamics of ERK activation in further detail, we used a genetic reporter of ERK activity. Briefly, the RCS<sup>Fgfr1</sup> cells were transfected with the transcriptional reporter pKrox24 (<xref ref-type="bibr" rid="bib24">Gudernova et al., 2017</xref>), engineered to induce the expression of eGFP upon ERK pathway activation. The pKrox signal was monitored for 48 hr by automated widefield microscopy. Significant differences in pKrox24 transactivation were found, with FGF4 inducing the strongest signal, in both magnitude and duration, compared to FGF9 and FGF8. Significant differences were also observed between FGF8 and FGF9-induced ERK activation (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="supplementary-material" rid="fig1sdata6">Figure 1—source data 6</xref>). These experiments showed that the three FGF ligands induce differential activation of ERK in RCS chondrocytes, consistent with the genetic ablation experiments (<xref ref-type="bibr" rid="bib53">Mariani et al., 2008</xref>), and prompted studies into the mechanism behind these differences.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Activation of FGF signaling in RCS^Fgfr1 cells.</title><p>(<bold>A</bold>) Expression of FGFR1 and FGFR2 in wild-type rat chondrosarcoma (RCS) cells, RCS cells <italic>null</italic> for FGFR1–4, and RCS cells expressing only endogenous FGFR1 (RCS<sup>Fgfr1</sup>). Actin serves as a loading control; n, number of biologically independent experiments. (<bold>B</bold>) RCS<sup>Fgfr1</sup> cells were treated with FGF4, FGF8, and FGF9 for indicated times and ERK phosphorylation (pErk) was monitored by western blot. Vinculin serves as a loading control. pErk signal was quantified and graphed (right) as relative values compared to the 10’ FGF4 stimulation; data show average and SEM of six biologically independent experiments. (<bold>C</bold>) RCS<sup>Fgfr1</sup> expressing the pKrox(MapERK)d1EGFP reporter were treated with FGF4, FGF8, and FGF9 and pKrox24 transactivation was monitored for 48 hr.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original files for the western blots in <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88144-fig1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig1">Figure 1A</xref> and original western blots.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88144-fig1-data2-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title>Original files for the western blots in <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88144-fig1-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig1">Figure 1B</xref> and original western blots.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88144-fig1-data4-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig1sdata5"><label>Figure 1—source data 5.</label><caption><title>Data plotted in <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig1-data5-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata6"><label>Figure 1—source data 6.</label><caption><title>Data plotted in <xref ref-type="fig" rid="fig1">Figure 1C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig1-data6-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88144-fig1-v1.tif"/></fig></sec><sec id="s2-2"><title>Differences in FGF-induced FGFR1 oligomerization</title><p>While most RTKs signal as dimers, it has been reported that under some conditions RTKs can form oligomers with different signaling capabilities (<xref ref-type="bibr" rid="bib82">Singh et al., 2018</xref>). Therefore, we considered the possibility that FGF4, FGF8, and FGF9 promote the formation of different types of FGFR1 oligomers in the plasma membrane. We thus assessed the association state of FGFR1, labeled with YFP, using fluorescence intensity fluctuations (FIF) spectrometry. The fluorophores were attached to the C-terminus of FGFR1 via a GGS flexible linker; this attachment has been used before and has been shown to not affect function (<xref ref-type="bibr" rid="bib75">Sarabipour and Hristova, 2016</xref>). The FIF experiments utilized 293T cells stably transfected with FGFR1-YFP.</p><p>FIF calculates molecular brightness of the YFP-tagged receptors in small regions of the cell membrane (<xref ref-type="bibr" rid="bib86">Stoneman et al., 2019</xref>). The molecular brightness, defined as the ratio of the variance of the fluorescence intensity within a membrane region to the mean fluorescence intensity in this region, is proportional to the oligomer size (<xref ref-type="bibr" rid="bib12">Digman and Gratton, 2012</xref>). The molecular brightness distributions of monomeric (linker for activation of T-cells [LAT]; gray) (<xref ref-type="bibr" rid="bib65">Paul et al., 2021</xref>; <xref ref-type="bibr" rid="bib64">Paul et al., 2020</xref>) and dimeric (TrkA in the presence of 130 nM nerve growth factor [NGF]; black) (<xref ref-type="bibr" rid="bib1">Ahmed et al., 2021</xref>) controls in 293T cells are shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref>; along with the brightness distribution for FGFR1 in 293T cells stably expressing FGFR1-YFP (red). We found that FGFR1, in the absence of ligand (red line), exists in a monomer/dimer equilibrium, as its brightness distribution is between the distributions of LAT (monomer control) and TrkA in the presence of saturating concentration of NGF (dimer control). The FIF experiments also report on the concentration of the receptors at the cell surface, which we find to be in the range 100–200 FGFR1/μm<sup>2</sup> in the stable cell line. This concentration is similar to previously reported FGFR expression levels of the order of ~80,000 receptors/cell, corresponding to ~80–100 receptors/μm<sup>2</sup> (<xref ref-type="bibr" rid="bib56">Moscatelli, 1987</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The oligomerization state of FGFR1, as measured by fluorescence intensity fluctuation (FIF) spectrometry.</title><p>(<bold>A</bold>) Brightness distributions shown on the linear scale. Brightness scales with the oligomer size. Linker for activation of T-cells (LAT) (gray) is a monomer control, TrkA+130 nM nerve growth factor (NGF) (black) is a dimer control. EphA2 bound to ephrinA1-Fc (brown) is an oligomer control. All distributions are scaled to a maximum of 1. (<bold>B</bold>) Distributions of log(brightness). Points represent the experimental FIF data, and the solid lines are the best-fit Gaussians. (<bold>C</bold>) Means of the best-fit Gaussians and the standard errors of the mean. Each data set is derived from at least 100 cells in three biologically independent experiments.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Fluorescence intensity fluctuations (FIF) brightness value distributions.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88144-fig2-v1.tif"/></fig><p>Next, we performed FIF experiments in the presence of FGF4, FGF8, and FGF9. The FGFs were added at high concentrations (130 nM), which exceed the reported FGF binding constants (in the ~nM range) (<xref ref-type="bibr" rid="bib71">Roghani et al., 1994</xref>; <xref ref-type="bibr" rid="bib20">Gleizes et al., 1995</xref>) such that all FGFR1 molecules are FGF-bound. The brightness distributions in the presence of the FGFs are shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref> (<xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). We see that the brightness distributions recorded in the presence of FGF8 (green) and FGF9 (blue) overlap with the distribution for the dimer control, while the distribution for FGF4 (orange) appears shifted to higher brightness. In fact, these data fall between the dimer control and the large oligomer control (EphrinA1+ephrinA1-Fc) (<xref ref-type="bibr" rid="bib82">Singh et al., 2018</xref>; <xref ref-type="bibr" rid="bib80">Seiradake et al., 2013</xref>; <xref ref-type="bibr" rid="bib79">Seiradake et al., 2010</xref>; <xref ref-type="bibr" rid="bib58">Nikolov et al., 2014</xref>). This brightness distribution suggests that the average oligomer size may be increased beyond a dimer in the presence of FGF4. We analyzed the likelihood of this possibility using a statistical test. Since the distributions of molecular brightness are log-normal, we analyzed the corresponding log(brightness) distributions which are Gaussian (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The parameters of the Gaussian distributions and the standard errors were calculated and used in a Z-test. Results, shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>, show that there are statistically significant differences (Z&gt;2, <xref ref-type="bibr" rid="bib2">Anderson et al., 2001</xref>) between the FGFR1 brightness distribution in the FGF4 case and the distribution for the dimer control (TrkA+NGF). Likewise, there are statistically significant differences between the FGFR1+FGF4 brightness distribution, on one hand, and the FGFR1+FGF8 and FGFR1+FGF9 brightness distributions, on the other (Z&gt;2). Further, the distributions measured for FGFR1+FGF8 and FGFR1+FGF9 are the same as the dimer control distribution. This analysis suggests that while FGF8-bound and FGF9-bound FGFR1 forms dimers, FGF4 binding may promote the formation of higher order FGFR1 oligomers.</p></sec><sec id="s2-3"><title>Differences in FGFR1 phosphorylation dose-response curves</title><p>Next, we studied FGFR1 signaling in response to FGF4, FGF8, and FGF9 using quantitative western blotting. In particular, we acquired FGFR1 dose-response curves while varying the concentrations of FGF4, FGF8, or FGF9 over a broad range. As we sought mechanistic interpretation of the results, we used the same 293T cell line used in the FIF experiments, since the FGFR1 expression and the FGFR1 oligomer size in the cell line are known.</p><p>The cells were incubated with FGFs for 20 min at 37°C, after which the cells were lysed, and the lysates were subjected to SDS-PAGE while probing with antibodies recognizing specific phospho-tyrosine motifs. We assessed several responses: (i) phosphorylation of Y653/654, which are the two tyrosines in the activation loop of the FGFR1 kinase that are required for kinase activity (<xref ref-type="bibr" rid="bib21">Goetz and Mohammadi, 2013</xref>; <xref ref-type="bibr" rid="bib78">Schlessinger, 2004</xref>; <xref ref-type="bibr" rid="bib19">Furdui et al., 2006</xref>; <xref ref-type="bibr" rid="bib47">Lew et al., 2009</xref>); (ii) phosphorylation of Y766 in the kinase tail of FGFR1, which serves as a binding site for PLCγ (<xref ref-type="bibr" rid="bib85">Sorokin et al., 1994</xref>); (iii) phosphorylation of FRS2, which is an adaptor protein that is constitutively associated with FGFR1 through interactions that do not involve phosphorylated tyrosines (<xref ref-type="bibr" rid="bib6">Burgar et al., 2002</xref>; <xref ref-type="bibr" rid="bib23">Gotoh, 2008</xref>); and (iv) phosphorylation of PLCγ, which binds to Y766 (<xref ref-type="bibr" rid="bib98">Yang et al., 2016</xref>). In addition, we blotted for the total expression of FGFR1, thus assaying for ligand-induced FGFR1 downregulation. Typical western blots are shown in <xref ref-type="fig" rid="fig3">Figure 3A</xref>. The band intensities from at least three independent experiments were quantified for each ligand concentration. The dose-response curves for different ligands were placed on a common scale by re-running some of the samples on a common gel, as shown in <xref ref-type="fig" rid="fig3">Figure 3B</xref>, and by following the scaling protocol in Materials and methods. The scaled dose-response curves are shown in <xref ref-type="fig" rid="fig3">Figure 3C</xref>; <xref ref-type="supplementary-material" rid="fig3sdata4 fig3sdata5 fig3sdata6 fig3sdata7">Figure 3—source data 4–7</xref>.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Phosphorylation of FGFR1 and downstream signaling substrates in HEK 293T cells.</title><p>(<bold>A</bold>) Sample western blots for Y653/4 FGFR1 phosphorylation and FRS2 phosphorylation in response to FGF4, FGF8, and FGF9. (<bold>B</bold>) An example blot used for data scaling, where samples with maximum phosphorylation in response to FGF4, FGF8, and FGF9 are re-run on the same gel. (<bold>C</bold>) Dose-response curves from the western blot experiments. The points represent the averaged data, mean ± SEM, while the solid lines are the best-fit rectangular hyperbolic curves. Fit parameters are shown in <xref ref-type="table" rid="table1">Table 1</xref>. Data are from three to five biologically independent experiments.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original files for the western blots in <xref ref-type="fig" rid="fig3">Figure 3A and B</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88144-fig3-data1-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig3">Figure 3A and B</xref> and original western blots.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88144-fig3-data2-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>pY653/654 phosphorylation dose-response curves.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88144-fig3-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>Y766 phosphorylation dose-response curves.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig3-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata5"><label>Figure 3—source data 5.</label><caption><title>pPLCγ phosphorylation dose-response curves.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig3-data5-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata6"><label>Figure 3—source data 6.</label><caption><title>pFRS2 phosphorylation dose-response curves.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig3-data6-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata7"><label>Figure 3—source data 7.</label><caption><title>Fibroblast growth factor receptor (FGFR) downregulation dose-response curves.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig3-data7-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88144-fig3-v1.tif"/></fig><p><xref ref-type="fig" rid="fig3">Figure 3C</xref> reveals unexpected differences in the shape of the dose-response curves. While the FGF8 and FGF9 dose-response curves appear sigmoidal when plotted on a semi-log scale, as expected for a rectangular hyperbolic curve (<xref ref-type="disp-formula" rid="equ4">Equation 1</xref>), FGF4 exhibits an increase in phosphorylation up to 2.6 nM, followed by a marked decrease in phosphorylation for all studied responses with further increasing FGF4 concentration.</p><p>What could explain the very unusual FGF4 dose-response curves in <xref ref-type="fig" rid="fig3">Figure 3C</xref>? We first considered the possibility that the shape of the FGF4 dose response is due to strong FGF4-induced FGFR1 degradation at high FGF4 concentrations. Data in <xref ref-type="fig" rid="fig3">Figure 3C</xref>, however, do not support this view as the effect of FGF4 on FGFR1 downregulation is smaller when compared to the effects of FGF8 and FGF9. Thus, differential ligand-induced FGFR1 degradation cannot explain the shape of the dose-response curves.</p><p>We next considered the possibility that the shape of the FGF4 dose-response curve is due to differential FGFR1 de-phosphorylation kinetics. In particular, we asked whether at high FGF concentration, a fast de-phosphorylation occurs for FGF4-bound FGFR1, while the de-phosphorylation of FGF8-bound and FGF9-bound FGFR1 is slower. As the western blot data were acquired after 20 min of stimulation, such differences in kinetics could explain the shape of the dose response. We thus measured Y653/654 phosphorylation via western blotting as a function of time, when 130 nM FGF was added to the cells for a duration of 0, 1, 5, 10, 20, and 60 min. The averages of three independent experiments are shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>, along with the standard errors. We see a quick increase in phosphorylation over time, followed by a decrease which may be due to FGFR1 de-phosphorylation and/or FGFR1 downregulation. Notably, the phosphorylation decrease in response to FGF4 is very similar when compared to the decrease in the presence of FGF9, while the FGF8-induced phosphorylation decrease is smaller. Thus, the FGF4-induced de-phosphorylation kinetics are not fundamentally different when compared to the FGF9 results and cannot provide an explanation for the observed decrease in FGFR1 phosphorylation at high FGF4 concentration.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>FGFR1 phosphorylation as a function of time after ligand addition.</title><p>(<bold>A</bold>) Phosphorylation time course of Y653/654 at high ligand concentration (130 nM). (<bold>B</bold>) Phosphorylation time course of Y653/654 at low ligand concentration (2.6 nM). (<bold>C</bold>) Phosphorylation time course of FRS2 at high ligand concentration (130 nM). (<bold>D</bold>) Phosphorylation time course of FRS2 at low ligand concentration (2.6 nM). Shown are means and standard errors of replicates from three biologically independent experiments.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>All kinetics data plotted in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88144-fig4-v1.tif"/></fig><p>Another possible explanation for the shape difference in the dose-response curves could be that the FGF4-stabilized FGFR1 oligomers, observed in the FIF experiments at high FGF4 concentration (<xref ref-type="fig" rid="fig2">Figure 2</xref>), are less active than the FGFR1 dimers. To gain further insights into FGF4-induced FGFR1 oligomerization, we performed FIF experiments in the presence of 2.6 nM FGF4, which corresponds to the peak of Y653/654 phosphorylation in the FGF4 dose-response curve. The brightness distribution at 2.6 nM FGF4, shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>, lies between the monomer control and the dimer control. The Z-test analysis shows that the 2.6 nM FGF4 brightness distribution is significantly different from both the monomer and dimer control distributions, as well as from the distribution observed in the presence of high FGF4 concentration. Thus, at low FGF4 concentration, FGFR1 exists primarily in monomeric and dimeric states, while higher FGF4 concentrations (&gt;2.6 nM FGF4) induce the formation of FGFR1 oligomers. The increase in phosphorylation at low FGF4 concentration can therefore be associated with FGFR1 dimers, while the subsequent phosphorylation decrease could be correlated with the appearance of oligomers in addition to dimers. Therefore, the assumption that FGFR1 oligomers are less active than FGFR1 dimers could provide an explanation for the observed shape of the FGF4 dose-response curves.</p></sec><sec id="s2-4"><title>Differences in phosphorylation potencies and efficacies, and demonstration of ligand bias</title><p>We next analyzed the dose-response curves in <xref ref-type="fig" rid="fig3">Figure 3C</xref> to determine the potencies and the efficacies of FGF4, FGF8, and FGF9. These two parameters were determined as optimal fit parameters in the context of rectangular hyperbolic dose-response curves (see <xref ref-type="disp-formula" rid="equ4">Equation 1</xref>), as done in the G-protein coupled receptor (GPCR) literature (<xref ref-type="bibr" rid="bib67">Rajagopal et al., 2011</xref>; <xref ref-type="bibr" rid="bib34">Kenakin and Christopoulos, 2013</xref>; <xref ref-type="bibr" rid="bib35">Kenakin, 2016</xref>). The efficacy (E<sub>top</sub> in <xref ref-type="disp-formula" rid="equ4">Equation 1</xref>) is the highest possible response that can be achieved for a ligand, typically at high ligand concentration. The potency (EC<sub>50</sub> in <xref ref-type="disp-formula" rid="equ4">Equation 1</xref>), on the other hand, is the ligand concentration that produces 50% of the maximal possible response for a given ligand. A highly potent ligand will evoke a certain response at low concentrations, while a ligand of lower potency will evoke the same response at much higher concentration.</p><p>The fitting of the FGF4 dose-response curves presented a particular challenge, as we could only fit the increasing portions of the dose-response curves to a rectangular hyperbolic curve. As described in Materials and methods, we truncated the data for the fit, including the data in the ascending portions of the curves and taking into account that the average errors in the western blots are 5–10%. In particular, we truncated all the acquired dose-response curves at the highest ligand concentration that is within 10% of the maximum response value. Under the assumption that the decrease in the FGF4 dose-response curve is due to oligomerization at high ligand concentration, the best-fit FGF4 dose-response curves represent the response of the FGFR1 dimers to FGF4.</p><p>The best fits for all dose-response curves are shown in <xref ref-type="fig" rid="fig3">Figure 3C</xref> with the solid lines. The best-fit values of E<sub>top</sub> and EC<sub>50</sub> for all studied responses are shown in <xref ref-type="table" rid="table1">Table 1</xref>. FGF4 exhibits the highest potency, followed by either FGF8 or FGF9, dependent of the particular response. FGF8 exhibits the highest efficacy, followed by either FGF4 or FGF9, dependent of the particular response. In most cases, FGF8 is a full agonist, while FGF9 and FGF4 are partial agonists. However, FGF4 and FGF8 appear to be both full agonists when FRS2 phosphorylation is probed (see <xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Best-fit parameters for dose-response curves in <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig5">5</xref>.</title><p>EC<sub>50</sub> is the potency of the ligand, and E<sub>top</sub> is the efficacy (see <xref ref-type="disp-formula" rid="equ4">Equation 1</xref>).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="3">pY653/4</th><th align="left" valign="bottom" colspan="3">PLCγ</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">EC<sub>50</sub>, M</td><td align="left" valign="bottom">E<sub>top</sub></td><td align="left" valign="bottom"/><td align="left" valign="bottom">EC<sub>50</sub>, M</td><td align="left" valign="bottom">E<sub>top</sub></td></tr><tr><td align="left" valign="bottom">FGF4</td><td align="left" valign="bottom">4.77E-10±0.42E-10</td><td align="left" valign="bottom">0.95±0.03</td><td align="left" valign="bottom">FGF4</td><td align="char" char="hyphen" valign="bottom">7.98E-11±2.15E-11</td><td align="char" char="plusmn" valign="bottom">0.80±0.04</td></tr><tr><td align="left" valign="bottom">FGF8</td><td align="left" valign="bottom">1.04E-8±0.23E-8</td><td align="left" valign="bottom">1.11±0.07</td><td align="left" valign="bottom">FGF8</td><td align="char" char="hyphen" valign="bottom">1.05E-9±0.23E-9</td><td align="char" char="plusmn" valign="bottom">0.99±0.03</td></tr><tr><td align="left" valign="bottom">FGF9</td><td align="left" valign="bottom">2.09E-9±0.31E-9</td><td align="left" valign="bottom">0.70±0.02</td><td align="left" valign="bottom">FGF9</td><td align="char" char="hyphen" valign="bottom">2.05E-10±0.40E-10</td><td align="char" char="plusmn" valign="bottom">0.62±0.02</td></tr><tr><th align="left" valign="bottom" colspan="3">pY766</th><th align="left" valign="bottom" colspan="3">pFRS2</th></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">EC<sub>50</sub>, M</td><td align="left" valign="bottom">E<sub>top</sub></td><td align="left" valign="bottom"/><td align="left" valign="bottom">EC<sub>50</sub>, M</td><td align="left" valign="bottom">E<sub>top</sub></td></tr><tr><td align="left" valign="bottom">FGF4</td><td align="left" valign="bottom">5.84E-10±1.26E-10</td><td align="left" valign="bottom">0.76±0.05</td><td align="left" valign="bottom">FGF4</td><td align="char" char="hyphen" valign="bottom">3.42E-10±0.70E-10</td><td align="char" char="plusmn" valign="bottom">0.94±0.06</td></tr><tr><td align="left" valign="bottom">FGF8</td><td align="left" valign="bottom">1.42E-8±0.25E-8</td><td align="left" valign="bottom">1.16±0.07</td><td align="left" valign="bottom">FGF8</td><td align="char" char="hyphen" valign="bottom">1.62E-9±0.29E-9</td><td align="char" char="plusmn" valign="bottom">0.98±0.03</td></tr><tr><td align="left" valign="bottom">FGF9</td><td align="left" valign="bottom">1.94E-9±0.71E-9</td><td align="left" valign="bottom">0.56±0.05</td><td align="left" valign="bottom">FGF9</td><td align="char" char="hyphen" valign="bottom">1.65E-9±0.15E-9</td><td align="char" char="plusmn" valign="bottom">0.52±0.01</td></tr><tr><th align="left" valign="bottom" colspan="3">FGFR1 Downregulation</th><th align="left" valign="bottom" colspan="3">Growth arrest</th></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">EC<sub>50</sub>, M</td><td align="left" valign="bottom">E<sub>top</sub></td><td align="left" valign="bottom"/><td align="left" valign="bottom">EC<sub>50</sub>, M</td><td align="left" valign="bottom">E<sub>top</sub></td></tr><tr><td align="left" valign="bottom">FGF4</td><td align="left" valign="bottom">7.34E-10±4.54E-10</td><td align="left" valign="bottom">0.27±0.04</td><td align="left" valign="bottom">FGF4</td><td align="char" char="hyphen" valign="bottom">2.59E-12±1.1E-13</td><td align="char" char="plusmn" valign="bottom">0.99±0.00</td></tr><tr><td align="left" valign="bottom">FGF8</td><td align="left" valign="bottom">1.39E-8±0.39E-8</td><td align="left" valign="bottom">0.63±0.05</td><td align="left" valign="bottom">FGF8</td><td align="char" char="hyphen" valign="bottom">1.60E-9±2.3E-10</td><td align="char" char="plusmn" valign="bottom">1.14±0.04</td></tr><tr><td align="left" valign="bottom">FGF9</td><td align="left" valign="bottom">6.80E-9±2.08E-9</td><td align="left" valign="bottom">0.42±0.02</td><td align="left" valign="bottom">FGF9</td><td align="char" char="hyphen" valign="bottom">5.89E-11±8.5E-12</td><td align="char" char="plusmn" valign="bottom">0.95±0.00</td></tr><tr><th align="left" valign="bottom" colspan="3">Collagen type 2 loss</th><th align="left" valign="bottom"/><th align="left" valign="bottom"/><th align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">EC<sub>50</sub>, M</td><td align="left" valign="bottom">E<sub>top</sub></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">FGF4</td><td align="left" valign="bottom">1.24E-11±2.79E-12</td><td align="left" valign="bottom">1.02±0.01</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">FGF8</td><td align="left" valign="bottom">8.51E-11±2.86E-11</td><td align="left" valign="bottom">0.77±0.03</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">FGF9</td><td align="left" valign="bottom">5.67E-11±2.89E-11</td><td align="left" valign="bottom">0.86±0.06</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><p>The results in <xref ref-type="table" rid="table1">Table 1</xref> show that the rank-ordering of the different ligands is different when different responses are probed, which is indicative of ligand bias. ‘Biased agonism’ or ‘ligand bias’ is the ability of different ligands to differentially activate different signaling pathways downstream of the same receptor (<xref ref-type="bibr" rid="bib25">Gundry et al., 2017</xref>). Ligand bias reflects not just quantitative differences in downstream signaling, but a fundamental difference between the signaling responses to different ligands (<xref ref-type="bibr" rid="bib36">Kenakin, 2019</xref>; <xref ref-type="bibr" rid="bib14">Ehlert, 2018</xref>). To determine if bias exists or not, we calculate bias coefficients using <xref ref-type="disp-formula" rid="equ5">Equation 2</xref>. Each bias coefficient, shown in <xref ref-type="table" rid="table2">Table 2</xref>, compares two responses and two ligands and reveals whether a response is preferentially engaged by one of the ligands (β≠0) or whether both responses are activated similarly by both ligands (β=0). We refer to the entire set of coefficients as a ‘bias map’.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Calculated bias coefficients using <xref ref-type="disp-formula" rid="equ5">Equation 2</xref>.</title><p>Gray shading indicates statistical significance between either FGF4 or FGF9 and the reference ligand FGF8 (see <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref> for p-values).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="bottom" colspan="3">β</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">4v8</td><td align="left" valign="bottom">9v8</td></tr><tr><td align="left" valign="bottom">pY653/4 vs pY766</td><td align="left" valign="bottom">–0.07±0.16</td><td align="left" valign="bottom">0.05±0.15</td></tr><tr><td align="left" valign="bottom">pY653/4 vs PLCγ</td><td align="left" valign="bottom">–0.24±0.18</td><td align="left" valign="bottom">0.01±0.14</td></tr><tr><td align="left" valign="bottom">pY653/4 vs pFRS2</td><td style="background-color: #E6E6E6;">–0.61±0.16</td><td style="background-color: #E6E6E6;">–0.78±0.12</td></tr><tr><td align="left" valign="bottom">pY766 vs pPLCγ</td><td align="left" valign="bottom">–0.18±0.19</td><td align="left" valign="bottom">–0.04±0.17</td></tr><tr><td align="left" valign="bottom">pY766 vs pFRS2</td><td style="background-color: #E6E6E6;">–0.54±0.17</td><td style="background-color: #E6E6E6;">–0.83±0.16</td></tr><tr><td align="left" valign="bottom">pPLCγ vs pFRS2</td><td align="left" valign="bottom">–0.37±0.20</td><td style="background-color: #E6E6E6;">–0.79±0.13</td></tr><tr><td align="left" valign="bottom">pY653/4 vs downregulation</td><td align="left" valign="bottom">–0.36±0.26</td><td align="left" valign="bottom">–0.36±0.16</td></tr><tr><td align="left" valign="bottom">pY766 vs downregulation</td><td align="left" valign="bottom">–0.29±0.27</td><td align="left" valign="bottom">–0.41±0.19</td></tr><tr><td align="left" valign="bottom">pPLCγ vs downregulation</td><td align="left" valign="bottom">–0.12±0.28</td><td align="left" valign="bottom">–0.37±0.16</td></tr><tr><td align="left" valign="bottom">pFRS2 vs downregulation</td><td align="left" valign="bottom">0.25±0.27</td><td align="left" valign="bottom">0.42±0.15</td></tr><tr><td align="left" valign="bottom">Collagen loss vs growth arrest</td><td style="background-color: #E6E6E6;">–1.77±0.20</td><td style="background-color: #E6E6E6;">–1.13±0.18</td></tr></tbody></table></table-wrap><p>We assessed statistical significance of the differences in bias coefficients for each pair of responses using ANOVA as described in Materials and methods. The results of the statistical analysis are shown in <xref ref-type="table" rid="table2">Table 2</xref>, where gray shading indicates statistical significance between either FGF4 or FGF9, on one hand, and the reference ligand FGF8, on the other. We see no statistical significance between FGF4 and FGF9 (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>).</p><p>Based on the ANOVA, we conclude that FGF8 is biased toward phosphorylation of FRS2, against phosphorylation of Y653/654 and Y766, and against PLCγ activation, as compared to FGF9. Furthermore, FGF8 is biased toward phosphorylation of FRS2 and against phosphorylation of Y653/654 and Y766, as compared to FGF4.</p></sec><sec id="s2-5"><title>Phosphorylation time courses cannot explain the existence of ligand bias</title><p>Previously, it has been suggested that ligand bias may arise due to differences in the time courses of phosphorylation (<xref ref-type="bibr" rid="bib18">Freed et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Kiyatkin et al., 2020</xref>). We therefore sought to compare the phosphorylation of the activation loop tyrosines Y653/654 and FRS2 over time. We chose these two particular responses because FGF8 is biased toward FRS2 and against Y653/654 FGFR1 phosphorylation, when compared to FGF4 and FGF9 (<xref ref-type="table" rid="table2">Table 2</xref>). Thus, we complemented the Y653/654 phosphorylation time course in <xref ref-type="fig" rid="fig4">Figure 4A</xref>; <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, acquired at high concentration (130 nM FGF), with kinetics measurements of Y653/654 phosphorylation at low (2.6 nM) FGF concentration, as well as FRS2 phosphorylation at low (2.6 nM) and high (130 nM ligand) FGF concentrations. Three independent time courses were acquired for each ligand-receptor pair, and the results were averaged. Data, scaled such that the maximal phosphorylation is set to 1, are shown in <xref ref-type="fig" rid="fig4">Figure 4B–D</xref>.</p><p>We observe differences in the time courses of Y653/654 and FRS2 phosphorylation. In the case of FRS2, we always observe fast accumulation of phosphorylated FRS2, which then decreases over time. Such a behavior has been observed for other RTKs and can be explained by the fact that auto-phosphorylation within the RTK dimers/oligomers occurs faster than phosphatase-mediated de-phosphorylation, after which a steady state is established (<xref ref-type="bibr" rid="bib87">Suwanmajo and Krishnan, 2013</xref>; <xref ref-type="bibr" rid="bib44">Lax et al., 2002</xref>). An early maximum in phosphorylation (at 5 min) is seen for FRS2 at both low and high FGF concentration, and is very pronounced for high FGF concentration. An early phosphorylation maximum is also observed for Y653/654 FGFR at high FGF concentration, but not at low FGF concentration.</p><p>When comparing the time courses of FGFR1 phosphorylation, in every panel of <xref ref-type="fig" rid="fig4">Figure 4</xref>; <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>, we do not see discernable differences in the time course of FGF8-induced phosphorylation, as compared to FGF4 or FGF9. Thus, the time course of phosphorylation alone cannot identify FGF8 as a biased ligand, when compared to FGF4 or FGF9.</p></sec><sec id="s2-6"><title>Differences in cellular responses and demonstration of functional bias</title><p>Biased signaling manifests itself in different cellular responses, which can be cell-specific (<xref ref-type="bibr" rid="bib36">Kenakin, 2019</xref>). We therefore investigated if 293T cells expressing FGFR1 respond differently when stimulated with FGF8 and FGF9. The effects of these two biased FGFs can be directly compared at high concentration as their phosphorylation responses come to a plateau (<xref ref-type="fig" rid="fig3">Figure 3</xref>). We compared FGFR1 clearance from the plasma membrane due to FGF-induced uptake, cell apoptosis, and cell viability for the 293T cells used in the western blotting experiments. These cellular responses have been previously reported to occur downstream of FGFR1 activation (<xref ref-type="bibr" rid="bib89">Tomlinson et al., 2009</xref>; <xref ref-type="bibr" rid="bib97">Xie et al., 2020</xref>; <xref ref-type="bibr" rid="bib96">Xian et al., 2007</xref>).</p><p>To study FGFR1 endocytosis, we measured the decrease in FGFR1-YFP concentration in the plasma membrane in response to a 2 min treatment of 130 nM of FGF8 or FGF9. After fixation, the plasma membranes in contact with the substrate were imaged on a confocal microscope, and the fluorescence intensities for hundreds of cells stimulated with either FGF8, FGF9, or no ligand were recorded. The average fluorescence intensities for the three groups, from three independent experiments, are shown in <xref ref-type="fig" rid="fig5">Figure 5A</xref>; <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>. We observed a decrease in fluorescence, corresponding to a decrease in plasma membrane concentration of FGFR1-YFP in response to FGF8, as compared to FGF9 and no ligand. This effect was statistically significant by ANOVA (p&lt;0.05). On the other hand, there were no statistically significant differences in FGFR1-YFP membrane concentrations between the FGF9-treated and control groups. These results indicate that FGF8 is more efficient at inducing FGFR1 removal from the plasma membrane immediately after ligand addition, as compared to FGF9. However, the total FGFR1 expression was not affected by a 2 min treatment with ligand (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>), consistent with the expectation that the FGF8-induced decrease in FGFR1 plasma membrane concentration in <xref ref-type="fig" rid="fig5">Figure 5A</xref> reflects enhanced internalization that precedes degradation.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Functional FGFR1-mediated responses to different ligands.</title><p>(<bold>A</bold>) FGFR1 concentration in the plasma membrane of HEK 293T cells at t=2 min following ligand addition for FGF8, FGF9, and no ligand control. (<bold>B</bold>) HEK 293T cell viability after ligand exposure and 6 days of starvation for varying ligand concentrations. (<bold>C</bold>) Apoptosis of HEK 293T cells under starvation conditions, exposed to varying concentrations of FGF8 and FGF9. Results are summarized in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>. (<bold>D</bold>) RCS<sup>Fgfr1</sup> cells were treated with FGF4, FGF8, and FGF9 for 48 hr, and the levels of collagen type 2 were determined by western blot. Actin serves as a loading control. (<bold>E</bold>) Dose-response curves describing collagen type 2 loss. (<bold>F</bold>) Dose-response curves for growth arrest of RCS<sup>Fgfr1</sup> cells after 72 hr, in response to FGF4, FGF8, and FGF9. Data are from at least three biologically independent experiments.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>FGFR1 membrane concentration, cell viability, and apoptosis data plotted in <xref ref-type="fig" rid="fig5">Figure 5A, B, and C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><label>Figure 5—source data 2.</label><caption><title>Original files for the western blots in <xref ref-type="fig" rid="fig5">Figure 5D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88144-fig5-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5sdata3"><label>Figure 5—source data 3.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig5">Figure 5D</xref> and original western blots.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88144-fig5-data3-v1.pdf"/></supplementary-material></p><p><supplementary-material id="fig5sdata4"><label>Figure 5—source data 4.</label><caption><title>Collagen amounts, used to generate the dose-response curves for collagen type 2 loss in <xref ref-type="fig" rid="fig5">Figure 5E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig5-data4-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata5"><label>Figure 5—source data 5.</label><caption><title>Cell counts, used to generate the dose-response curves for growth arrest in <xref ref-type="fig" rid="fig5">Figure 5F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig5-data5-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88144-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Total cellular expression of FGFR1 in the stable FGFR1 line.</title><p>Shown are results for three different biologically independent samples in the absence of ligand, three samples that have been treated with FGF8 for 2 min, and three samples that have been treated with FGF9 for 2 min. All the expressions are the same.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Original files for the western blots in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-88144-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig5s1sdata2"><label>Figure 5—figure supplement 1—source data 2.</label><caption><title>PDF containing <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref> and original western blots.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88144-fig5-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88144-fig5-figsupp1-v1.tif"/></fig></fig-group><p>We next sought to measure and compare the relative amounts of live FGFR1-expressing 293T cells after stimulation with FGF and after 6 days of starvation, using an MTT assay. The read-out as a function of FGF concentration is shown in <xref ref-type="fig" rid="fig5">Figure 5B</xref>; <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>, revealing a modest decrease in cell viability with increasing concentration for both FGF8 and FGF9. Data were fitted to linear functions, and the slopes were compared using a t-test. Results show that there is a significant difference in cell viability when cells are stimulated with FGF8, as compared to FGF9 (p&lt;0.015). Further, the effects of the two ligands are significant when compared to the case of no FGF.</p><p>To monitor the apoptosis of cells exposed to different FGF8 and FGF9 concentrations, we used a commercial kit that measures the combined activity of caspases 3 and 7 (Magic Red Caspase Kit) through an increase in caspase substrate fluorescence. Experiments were conducted at 0, 20, 40, and 100 nM FGF, under starvation conditions, and the results for each set of experiments were scaled such that caspase activity was 1.0 in the absence of FGF. Data in <xref ref-type="fig" rid="fig5">Figure 5C</xref>; <xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref> show the scaled caspase activity as a function of FGF concentration. We see a significant increase in caspase activity in the case of FGF8, but not FGF9. Data were fitted to linear functions, and the best-fit slopes were compared using a t-test. The difference between the slopes was statistically significant (p&lt;0.005), indicating that FGF8 promotes apoptosis more efficiently than FGF9 in 293T cells. We thus observe that FGF8 is more efficient than FGF9 at promoting FGFR1 clearance from the plasma membrane, apoptosis, and cell viability under starvation conditions. This observation is a manifestation of the ligand bias seen upstream.</p><p>Since the FGF-induced effects on 293T cell responses were modest, and the dose-response curves did not exhibit rectangular hyperbolic shapes to allow bias coefficient calculations, we quantified two well-known functional responses of RCS cells to FGF treatment: growth arrest and loss of collagen type 2 expression (<xref ref-type="bibr" rid="bib16">Fafilek et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Krejci et al., 2010</xref>). We performed the experiments with the RCS<sup>Fgfr1</sup> cells used to acquire the data in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Collagen 2 amounts were measured using western blotting after 48 hr of treatment with FGFs at varying concentrations (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>, <xref ref-type="supplementary-material" rid="fig5sdata4">Figure 5—source data 4</xref>). Similarly, the growth arrest of RCS<sup>Fgfr1</sup> cells was determined after 72 hr of stimulation with the three FGFs (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, <xref ref-type="supplementary-material" rid="fig5sdata5">Figure 5—source data 5</xref>). The dose-response curves in <xref ref-type="fig" rid="fig5">Figure 5E and F</xref> are distinctly different from each other and all exhibit rectangular hyperbolic shapes. We see that FGF4, FGF8, and FGF9 have very different effects on the two functional responses that we quantified.</p><p>The dose-response curves were fitted using <xref ref-type="disp-formula" rid="equ4">Equation 1</xref> and the EC<sub>50</sub> and E<sub>top</sub> values are reported in <xref ref-type="table" rid="table1">Table 1</xref>. The three FGFs exhibit different potencies, with FGF4 being the most potent inducer of both responses. The potencies of FGF8 and FGF9 for collagen 2 reduction are similar, but their potencies to induce growth arrest differ significantly. The efficacies of the three ligands in inducing collagen 2 reduction are different, with FGF4 behaving as full agonist and FGF8 and FGF9 as partial agonists. The efficacies in inducing growth arrest are similar for the three FGFs.</p><p>The bias coefficients are reported in <xref ref-type="table" rid="table2">Table 2</xref>. FGF8 is strongly biased toward collagen loss and against growth arrest, when compared to FGF4 and FGF9. The effect is highly significant (<xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>).</p></sec><sec id="s2-7"><title>Structural determinants behind FGFR1 biased signaling</title><p>We sought possible structural determinants behind the observed FGF bias. For GPCRs, it is now well established that different GPCR ligands stabilize different receptor conformations, where each of the conformations has a preference for a subset of downstream signaling molecules (either G proteins or arrestins) (<xref ref-type="bibr" rid="bib29">Kahsai et al., 2011</xref>; <xref ref-type="bibr" rid="bib49">Liu et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">Kufareva et al., 2017</xref>; <xref ref-type="bibr" rid="bib100">Zheng et al., 2017</xref>; <xref ref-type="bibr" rid="bib91">Wacker et al., 2013</xref>). We therefore asked if structural differences in the FGF4, FGF8, and FGF9-bound FGFR1 dimers may explain bias for FGF8, as compared to FGF4 and FGF9.</p><p>It is known that FRS2 binds to the FGFR1 JM domain in a ligand-independent manner (<xref ref-type="bibr" rid="bib23">Gotoh, 2008</xref>; <xref ref-type="bibr" rid="bib59">Ong et al., 2000</xref>). It is also believed that the conformation of the JM domain of RTKs is influenced by the conformation of the TM domain dimer in response to ligand binding (<xref ref-type="bibr" rid="bib13">Doerner et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Scheck et al., 2012</xref>). Further, the FGFR1 TM domain has already been shown to sense the identity of the bound FGF, either FGF1 or FGF2, and adopt a different TM domain dimer conformation (<xref ref-type="bibr" rid="bib75">Sarabipour and Hristova, 2016</xref>). We therefore sought to investigate the possibility that the TM domains of FGFR1 self-associate differently when FGF8, as compared to FGF4 and FGF9, is bound to the FGFR1 EC domain.</p><p>A Förster resonance energy transfer (FRET)-based methodology has been instrumental in revealing differences in FGFR TM domain dimer conformations in response to FGF binding (<xref ref-type="bibr" rid="bib75">Sarabipour and Hristova, 2016</xref>). In these experiments, we monitored differences in the IC distances and relative orientation of fluorescent protein reporters when different ligands bind to the EC domain. We used truncated FGFR1 constructs, which contain the entire EC and TM domains of FGFR1 followed by a flexible linker and either mCherry or YFP. The fluorescent proteins mCherry and YFP are a FRET pair and thus report on the separation between the C-termini of the TM domains in a FGFR1 dimer (<xref ref-type="bibr" rid="bib75">Sarabipour and Hristova, 2016</xref>). Measurements were performed in plasma membrane-derived vesicles, as previously described (<xref ref-type="bibr" rid="bib73">Sarabipour et al., 2015</xref>). High concentration of ligand (250 nM) was used, to ensure that all receptors are ligand-bound. We followed a quantitative protocol (termed QI-FRET) which yields (i) the FRET efficiency, (ii) the donor concentration, and (iii) the acceptor concentration in each vesicle (<xref ref-type="bibr" rid="bib38">King et al., 2016</xref>). A few hundred vesicles, imaged in multiple independent experiments, were analyzed and the data were combined.</p><p><xref ref-type="fig" rid="fig6">Figure 6A</xref>, left (<xref ref-type="supplementary-material" rid="fig6sdata1">Figure 6—source data 1</xref>, <xref ref-type="supplementary-material" rid="fig6sdata2">Figure 6—source data 2</xref>, <xref ref-type="supplementary-material" rid="fig6sdata3">Figure 6—source data 3</xref>), shows the FRET efficiencies as a function of total FGFR1 concentration in the presence of the three ligands, where each data point corresponds to one individual vesicle derived from one cell. The total FGFR1 concentration, on the x axis in <xref ref-type="fig" rid="fig6">Figure 6A</xref>, left, is the sum of ECTM FGFR1-YFP and ECTM FGFR-mCherry concentrations. In <xref ref-type="fig" rid="fig6">Figure 6A</xref>, right, we further show the expressions of ECTM FGFR1-YFP and ECTM FGFR1-mCherry in the individual vesicles. Because transient expression levels vary from cell to cell, the vesicles produced in a single transfection experiment had a wide range of receptor concentrations.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Differences in FGFR1 transmembrane domain association in response to FGF ligands.</title><p>(<bold>A</bold> and <bold>B</bold>) Förster resonance energy transfer (FRET) data for ECTM-FGFR1-YFP and ECTM-FGFR1-mCherry in the presence of saturating FGF4 (orange), FGF8 (green), or FGF9 (blue) concentrations. (<bold>A</bold>) Measured FRET efficiencies versus total receptor (ECTM-FGFR1-YFP + ECTM-FGFR1-mCherry) concentrations and measured donor (ECTM-FGFR1-YFP) concentrations versus acceptor (ECTM-FGFR1-YFP) concentrations in single vesicles. (<bold>B</bold>) Histograms of single-vesicle intrinsic FRET values. Intrinsic FRET is a measure of the separation between the fluorescent proteins. Different intrinsic FRET values were measured for FGF8 and FGF4/FGF9. (<bold>C</bold>) Graphical representation of experimental results showing that in the presence of FGF8 the transmembrane (TM) C-termini are positioned further apart from each other, as compared to the cases of FGF4 and FGF9.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>FGF4 Förster resonance energy transfer (FRET) data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig6-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata2"><label>Figure 6—source data 2.</label><caption><title>FGF8 Förster resonance energy transfer (FRET) data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig6-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6sdata3"><label>Figure 6—source data 3.</label><caption><title>FGF9 Förster resonance energy transfer (FRET) data.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88144-fig6-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88144-fig6-v1.tif"/></fig><p>We see that the FRET efficiencies in <xref ref-type="fig" rid="fig6">Figure 6A</xref> do not depend on the concentration, over a broad receptor expression range, indicative of constitutive FGFR1 association in the presence of FGF4, FGF8, and FGF9. In this case, the FRET efficiency depends only on (i) the fraction of acceptor-labeled FGFR1, which is directly calculated from the data in <xref ref-type="fig" rid="fig6">Figure 6A</xref> and (ii) the so-called intrinsic FRET, a structural parameter which depends on the positioning and dynamics of the fluorophores (<xref ref-type="bibr" rid="bib7">Chen et al., 2010a</xref>). An intrinsic FRET value was calculated for each vesicle from the data in <xref ref-type="fig" rid="fig6">Figure 6A</xref> using <xref ref-type="disp-formula" rid="equ8">Equation 5</xref>. The values were binned to generate a histogram and are shown in <xref ref-type="fig" rid="fig6">Figure 6B</xref>; . These histograms were fitted with Gaussians, yielding intrinsic FRET values of 0.54±0.01, 0.42±0.01, and 0.52±0.01, for the cases of FGF4, FGF8, and FGF9, respectively. Thus, intrinsic FRET is lower for FGF8-bound ECTM FGFR1, as compared to FGF4 and FGF9-bound ECTM FGFR1. Since the fluorescent proteins were attached directly to the TM domains via flexible linkers, the measured differences in intrinsic FRET reflect differences in the separation of the C-termini of the TM domains in the presence of FGF8, compared to FGF4 and FGF9. Thus, the FGFR1 TM domains self-associate in different manner when FGF8 is bound, as compared to the cases when FGF4 or FGF9 are bound.</p><p>The effective distances between the fluorescent proteins in the ECTM FGFR1 dimers are calculated using <xref ref-type="disp-formula" rid="equ1">Equation 6</xref>, assuming random orientation of the fluorophores (justified because they were attached via flexible linkers). In the presence of FGF4 and FGF9, the effective distance between the fluorescent proteins is the same, 55±1 and 56±1 Å (p&gt;0.05). In the presence of FGF8, the effective distance between the fluorescent proteins is significantly higher, 60±1 Å (p&lt;0.01) as shown in <xref ref-type="fig" rid="fig6">Figure 6C</xref>. These structural differences may underlie the observed signaling bias in response to FGF8, as compared to FGF4 and FGF9.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The most significant discovery in this work is the existence of bias in FGFR1 signaling in response to three FGF ligands that are encountered during limb development. This concept of ‘ligand bias’ is a relatively novel concept in RTK research (<xref ref-type="bibr" rid="bib31">Karl et al., 2020</xref>). It describes the ability of ligands to differentially activate signaling pathways (<xref ref-type="bibr" rid="bib35">Kenakin, 2016</xref>; <xref ref-type="bibr" rid="bib25">Gundry et al., 2017</xref>; <xref ref-type="bibr" rid="bib84">Smith et al., 2018</xref>). Ligand bias has been studied primarily in the context of GPCRs and has transformed the fundamental understanding of GPCR signaling (<xref ref-type="bibr" rid="bib25">Gundry et al., 2017</xref>). Importantly, these investigations have produced optimized protocols to identify and quantify bias that are directly applicable to RTKs (<xref ref-type="bibr" rid="bib31">Karl et al., 2020</xref>). Here, we use such quantitative protocols to demonstrate that FGF8 but not FGF4 or FGF9 preferentially induces FRS2 phosphorylation, when compared to the phosphorylation of FGFR1 tyrosines. We also demonstrated that FGF8 preferentially induces collagen 2 loss over growth arrest, as compared to FGF4 and FGF9.</p><p>It must be noted that the term ‘RTK ligand bias’ is often used in the literature to indicate any difference in RTK signaling due to ligands. Here, we use this term in the context of its classical definition in pharmacology, namely the differential activation of at least <italic>two</italic> different signaling responses (<xref ref-type="bibr" rid="bib35">Kenakin, 2016</xref>; <xref ref-type="bibr" rid="bib25">Gundry et al., 2017</xref>; <xref ref-type="bibr" rid="bib84">Smith et al., 2018</xref>). The term ‘bias’ is distinctly different from the potencies and efficacies of a ligand for one particular response. For example, in <xref ref-type="fig" rid="fig5">Figure 5E</xref> we see that FGF8 has both lower potency and lower efficacy than FGF4, but these data cannot provide any information about bias. Bias can be assessed only if the data in <xref ref-type="fig" rid="fig5">Figure 5E</xref> are compared to the data in <xref ref-type="fig" rid="fig5">Figure 5F</xref>, leading us to conclude that FGF8 is biased toward collagen 2 loss and against growth arrest, as compared to FGF4, despite the fact that FGF8 has the lowest potency and the lowest efficacy in inducing collagen loss. Potency, efficacy, and bias describe distinct aspects of RTK signaling, yet the differences in these characteristics have not been explicitly considered in prior studies of FGF signaling.</p><p>Ligand bias studies require the comparison of at least two responses and at least two ligands (<xref ref-type="bibr" rid="bib35">Kenakin, 2016</xref>; <xref ref-type="bibr" rid="bib25">Gundry et al., 2017</xref>; <xref ref-type="bibr" rid="bib84">Smith et al., 2018</xref>). Prior studies of the effects of different FGFs on FGFR signaling have utilized BAF/3 cells (<xref ref-type="bibr" rid="bib60">Ornitz et al., 1996</xref>; <xref ref-type="bibr" rid="bib99">Zhang et al., 2006</xref>; <xref ref-type="bibr" rid="bib5">Buchtova et al., 2015</xref>). In these cells, only a single response, cell proliferation, can be quantified and compared, and thus these cells cannot be used for bias studies. In HEK 293T cells, the functional effects due to FGF4, FGF8, and FGF9 are modest (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>). However, here we were able to measure dose-response curves for two functional responses in engineered RCS<sup>Fgfr1</sup> cells (<xref ref-type="fig" rid="fig5">Figure 5E and F</xref>). These cells allow us to model processes occurring in the developing mammalian limb, where the three FGF ligands (FGF4, FGF8, FGF9) released by the ectoderm at the surface of the limb bud signal to the underlying mesenchymal cell which expresses just one FGF receptor, FGFR1c (<xref ref-type="bibr" rid="bib52">Mariani and Martin, 2003</xref>; <xref ref-type="bibr" rid="bib88">Tabin and Wolpert, 2007</xref>). In RCS cells, cellular phenotypes caused by FGF signaling can be quantified, and thus RCS cells have been used in studies exploring the mechanisms of FGF-FGFR signaling, including mechanisms behind FGF regulation of the cell cycle, cell proliferation, differentiation, premature senescence, loss of EC matrix, interplay between FGF and WNT signaling, cytokine and natriuretic peptide signaling, and others (<xref ref-type="bibr" rid="bib16">Fafilek et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Krejci et al., 2010</xref>; <xref ref-type="bibr" rid="bib68">Raucci et al., 2004</xref>; <xref ref-type="bibr" rid="bib66">Priore et al., 2006</xref>; <xref ref-type="bibr" rid="bib30">Kamemura et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Kolupaeva et al., 2013</xref>; <xref ref-type="bibr" rid="bib10">Dailey et al., 2003</xref>; <xref ref-type="bibr" rid="bib72">Rozenblatt-Rosen et al., 2002</xref>). In addition, treatments inhibiting pathological FGFR signaling, which are now either in human trials (RBM007, meclozine) or FDA-approved (vosoritide), were initially developed in RCS cells, benefiting from the well-characterized molecular mechanisms of FGF signaling in these cells (<xref ref-type="bibr" rid="bib37">Kimura et al., 2021</xref>; <xref ref-type="bibr" rid="bib92">Wendt et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Matsushita et al., 2013</xref>). Here, we show that RCS cells can also be used to identify biased FGF ligands.</p><p>Thus far, differential effects in the signaling of one FGFR in response to different FGF ligands have been attributed to differences in ligand binding. It can be reasoned, however, that differences in ligand binding strengths, alone, cannot explain differential signaling. Indeed, if the differences between ligands are only in the binding strength, then a strongly binding ligand, at low concentration, will act identically to weakly binding ligand at high concentration. Here, we discovered, using tools that are novel for the RTK field, that there are also qualitative differences in the actions of the ligands. FGF8 preferentially activates some of the probed downstream responses (FRS2 phosphorylation and collagen loss), while FGF4 and FGF9 preferentially activate different probed responses (FGFR1 phosphorylation and growth arrest). These effects occur in addition to previously measured differences in ligand binding coefficients (<xref ref-type="bibr" rid="bib55">Mohammadi et al., 2005</xref>).</p><p>Having established the existence of bias in FGFR1 signaling, we sought the mechanism that allows for the recognition of FGF8 binding to the FGFR1 EC domain, as compared to FGF4 and FGF9. We measured FRET efficiency when the fluorescent proteins were attached to the C-termini of the TM helices via flexible linkers. We showed that the FRET efficiency is different when FGF8 is bound to the EC domain, as compared to the cases of bound FGF4 and FGF9. These results suggest that the C-termini of the TM helices are spaced further apart when FGF8 is bound, as compared to FGF4 and FGF9. Thus, the FGFR1 TM domains must sense the identity of the ligand that is bound to the EC domain. FRS2 binds to the JM domain, which immediately follows the TM domain (<xref ref-type="bibr" rid="bib23">Gotoh, 2008</xref>; <xref ref-type="bibr" rid="bib59">Ong et al., 2000</xref>; <xref ref-type="bibr" rid="bib26">Hadari et al., 1998</xref>). It is easy to envision that the conformation of the TM domain affects FRS2 behavior, as the FRS2 binding site is just 32 amino acids from the TM domain C-terminus. The larger TM domain separation in the FGF8-bound FGFR1 dimers may facilitate the preferential phosphorylation of FRS2 over other sites. Alternatively, the smaller TM domain separation upon binding of FGF4 and FGF9 may disfavor FRS2 phosphorylation. Further, the differential phosphorylation of FRS2 may be due to a different mode of FRS2 binding to FGFR1, differences in the accessibility of FRS2 by the active site of the FGFR1 kinase, or different accessibility of FRS2 by phosphatases.</p><p>The experimental data in <xref ref-type="fig" rid="fig6">Figure 6</xref> hint at the possibility that ligand bias arises due to differences in FGFR1 dimer conformations. If this is so, then conformational differences in the signaling complex in the plasma membrane may underlie biased signaling for both RTKs and GPCRs, the two largest receptor families in the human genome. It is important to note, however, that there are researchers who disagree that structural information can be propagated along the length of the RTK, because the linkers between the RTK domains are flexible (<xref ref-type="bibr" rid="bib18">Freed et al., 2017</xref>; <xref ref-type="bibr" rid="bib50">Lu et al., 2010</xref>; <xref ref-type="bibr" rid="bib3">Bocharov et al., 2017</xref>). If so, how do the kinases sense which ligand is bound to the EC domain? Some have proposed that differential downstream signaling occurs as a result of different kinetics of receptor phosphorylation/de-phosphorylation in response to different ligands (<xref ref-type="bibr" rid="bib18">Freed et al., 2017</xref>). There is a report that tyrosine phosphorylation of EGFR is more sustained in response to epigen and epiregulin than to EGF (<xref ref-type="bibr" rid="bib18">Freed et al., 2017</xref>). Specifically, it was found that EGF-induced EGFR phosphorylation of Y845, Y1086, and Y1173 returned to baseline much faster, as compared to phosphorylation in response to epigen and epiregulin (<xref ref-type="bibr" rid="bib18">Freed et al., 2017</xref>). The authors argued that differences in kinetics do not depend on the specific ligand concentration used, and they attributed the characteristic kinetics of the response to the identity of the bound ligand. In studies with other RTKs, however, the concentration of the ligand strongly influenced the kinetics of the response, questioning the applicability of this model to all RTKs (<xref ref-type="bibr" rid="bib95">Wykosky et al., 2008</xref>; <xref ref-type="bibr" rid="bib22">Gomez-Soler et al., 2019</xref>). Here, we show that FGFR1 kinetics of phosphorylation also depend strongly on FGF concentration. Furthermore, we do not observe a discernable correlation between kinetics of FGFR1 phosphorylation and ligand bias.</p><p>In this study, we observe marked differences in the potencies of the three FGFs. Indeed, 50% of maximum phosphorylation in 293T cells is reached for ~0.5 nM FGF4, ~2 nM FGF9, and ~10 nM FGF8. Thus, the same level of phosphorylation of a specific tyrosine can be achieved for much lower concentrations of FGF4, as compared to FGF8 or FGF9. The potencies of FGF4 in inducing functional responses are also the highest in RCS cells. We also observe differences in the efficacies of the three FGF ligands. The highest phosphorylation in <xref ref-type="fig" rid="fig3">Figure 3</xref> is achieved in response to high concentrations of FGF8. Thus, FGF8 is a full agonist while FGF4 and FGF9 are partial agonists for most of the responses (with the exception of FRS2 phosphorylation). Along with differences in potencies and efficacies, we observe a significant difference in the very shape of the dose-response curves. In particular, the FGF4 dose response does not follow the anticipated rectangular hyperbolic shape, unlike the cases of FGF8 and FGF9. We see that the FGF4-induced phosphorylation of FGFR1 and the effector molecules increases up to ~3 nM FGF4, and then gradually decreases as FGF4 concentration is further increased. The mechanism behind the decrease in activation at high FGF4 concentration is unknown, but our data suggest that it cannot be explained with differential kinetics of de-phosphorylation/downregulation. Furthermore, there is no correlation between the unusual shape of the FGF4 dose response and ligand bias, as FGF4 is not biased when compared to FGF9. Instead, we see an intriguing correlation between the decrease in FGFR1 phosphorylation and the appearance of FGFR1 oligomers that are larger than dimers. Indeed, the FIF data in <xref ref-type="fig" rid="fig2">Figure 2</xref> suggests that high FGF4 concentration promotes oligomerization of FGFR1. Oligomers are observed in full-length FGFR when bound to FGF4, but not when the kinase domains are deleted (based on FIF measurements). This finding suggests that, at least in part, the oligomers are stabilized by kinase-kinase contacts.</p><p>We can explain the shape of the FGF4 dose-response curves if we assume that phosphorylation is less efficient in FGFR1 oligomers as compared to FGFR1 dimers. It is important to note that EGFR has also been proposed to form oligomers in response to EGF, in addition to dimers (<xref ref-type="bibr" rid="bib57">Needham et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Huang et al., 2016</xref>). EGFR dimers and oligomers have been proposed to have different activities (<xref ref-type="bibr" rid="bib57">Needham et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Huang et al., 2016</xref>). It has been suggested that in the EGFR oligomer, each EGFR kinase may be able to phosphorylate and be phosphorylated by multiple neighboring kinases, leading to higher overall activation. Such a view, however, is not consistent with the FGFR1 data presented here. Perhaps, the functional role of FGFR1 oligomers is very different from that of the EGFR oligomers, as oligomerization seems to inhibit FGFR1 signaling.</p><p>In conclusion, we initiated this study in search of a possible difference in the response of FGFR1 to three FGF ligands. We found not one, but many differences. We observed quantitative differences in most aspects of the FGFR1 signaling response: ligand-induced oligomerization, potency, efficacy, and conformations of FGFR1 TM domain dimers. We also discovered the existence of ligand bias in FGFR1 signaling. The quantitative tools that we used were instrumental in revealing these differences, based on the analysis of FGFR1 dose-response curves for the three ligands. Of note, such dose-response curves are typically collected for GPCRs (<xref ref-type="bibr" rid="bib36">Kenakin, 2019</xref>; <xref ref-type="bibr" rid="bib51">Luttrell, 2014</xref>; <xref ref-type="bibr" rid="bib9">Correll and McKittrick, 2014</xref>; <xref ref-type="bibr" rid="bib33">Kenakin, 2011</xref>), but rarely for RTKs. Future use of such quantitative tools for other RTKs may similarly reveal unexpected differences in response to different ligands and may uncover exciting new biology.</p><p>All 58 RTKs have been implicated in many growth disorders and cancers (<xref ref-type="bibr" rid="bib46">Lemmon and Schlessinger, 2010</xref>; <xref ref-type="bibr" rid="bib70">Robertson et al., 2000</xref>; <xref ref-type="bibr" rid="bib4">Browne et al., 2009</xref>; <xref ref-type="bibr" rid="bib48">Li and Hristova, 2006</xref>), and have been recognized as important drug targets. Inhibitors that specifically target the RTKs have been under development for decades now. Recent years have seen significant improvements in RTK-targeted molecular therapies, but these therapies have not yet fundamentally altered the survival and the quality of life of patients (<xref ref-type="bibr" rid="bib45">Le et al., 2021</xref>; <xref ref-type="bibr" rid="bib43">Kumar et al., 2020</xref>). This limited progress may be because RTK signaling is much more complex than currently appreciated, as demonstrated here for FGFR1. Furthermore, it is possible that ligand bias plays an important role in RTK-linked pathologies. The practice of evaluating bias for novel RTK-targeting therapeutics may empower the discovery of a new generation of biased RTK inhibitors that selectively target pathogenic signaling pathways, and thus exhibit high specificity and low toxicity.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Fgfr1 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">9740</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Fgfr2 (rabbit polyclonal)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">sc122</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Collagen 2 (rabbit polyclonal)</td><td align="left" valign="bottom">Cedarlane</td><td align="left" valign="bottom">CL50241AP</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Actin (mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">3700</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Vinculin (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">13901</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">pERK (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">9101</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Y653/654 (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">3471S</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-pY766 FGFR1 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">2544S</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-pFRS2 (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">3861S</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-pPLCγ (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">2821S</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-PLCγ (rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">2822S</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-V5 (mouse monocolonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">46-0705</td><td align="left" valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody (secondary)</td><td align="left" valign="bottom">Anti-rabbit</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">W4011</td><td align="left" valign="bottom">(1:10,000)</td></tr><tr><td align="left" valign="bottom">Antibody (secondary)</td><td align="left" valign="bottom">Anti-mouse</td><td align="left" valign="bottom">Millipore Sigma</td><td align="left" valign="bottom">A6782</td><td align="left" valign="bottom">(1:10,000)</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HEK 293T FGFR1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Stable cell line developed and maintained by Hristova lab, identity authenticated by SRT profiling, negative for mycoplasma</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Rattus norvegicus</italic>)</td><td align="left" valign="bottom">RCS WT</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/7499238/">749928</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">A gift from Benoit de Crombrugghe</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Rattus norvegicus</italic>)</td><td align="left" valign="bottom">RCS Fgfr1-4 null</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/33952673/">33952673</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Rattus norvegicus</italic>)</td><td align="left" valign="bottom">RCS<sup>Fgfr1</sup></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Progenitors: Fgfr3/4 KO RCS cells from Carmine Settembre, identity authenticated by SRT profiling, negative for mycoplasma</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2× Laemmli Buffer</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">1610737</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tris/Gly/SDS running buffer</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">1610732</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Transfer buffer</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">1610734</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fugene HD</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">E2311</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Bio-Rad Mini-Protean TGX precast gels</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">4561026</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">PVDF membranes</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">1620177</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">West Femto Supersignal</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">1706435</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Bio-Rad Magic Red Caspase 3-7 kit</td><td align="left" valign="bottom">Bio-Rad</td><td align="left" valign="bottom">ICT 935</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">MTT Cell Proliferation Assay Kit</td><td align="left" valign="bottom">Cell BioLabs</td><td align="left" valign="bottom">CBS-252</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Iblot 2 Gel Transfer Device</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">IB21001</td><td align="left" valign="bottom">Equipment for transfer</td></tr><tr><td align="left" valign="bottom">Gene (<italic>Rattus norvegicus</italic>)</td><td align="left" valign="bottom"><italic>Fgfr1</italic></td><td align="left" valign="bottom">Ensembl</td><td align="left" valign="bottom">Ensembl:ENSRNOG00000016050</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">FGF4</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">235-F4-025</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">FGF8</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">423-F8-025</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant Protein</td><td align="left" valign="bottom">FGF9</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">273-F9-025</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">FGFR1-ECTM-eYFP (plasmid)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/26725515/">26725515</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">YFP-Dr M. Betenbaugh, FGFR1 in pRK5- Dr M Mohammadi, into pcDNA3.1 vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">FGFR1-ECTM-mCherry (plasmid)</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/26725515/">26725515</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom">pRSET-mCherry- Dr R.Tsien, FGFR1 in pRK5- Dr M Mohammadi, into pcDNA3.1 vector</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pKrox(MapERK)d1EGFP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Addgene plasmid #214912</td><td align="left" valign="bottom">Progenitors: pKrox24(MapErk)DsRed (PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/28199182/">28199182</ext-link>), pTR01F (PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/24376882/">24376882</ext-link>), d1EGFP (PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/16508309/">16508309</ext-link>), PCR of mEgr1 3’UTR</td></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">FIF software</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/31110281/">31110281</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Mathematica</td><td align="left" valign="bottom">Wolfram</td><td align="left" valign="bottom">13</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software</td><td align="left" valign="bottom">Prism</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">9.2.0</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture</title><p>Human embryonic kidney cells (HEK 293T), stably transfected with FGFR1-YFP, and RCS<sup>Fgfr1</sup> cells were grown in Dulbecco’s modified eagle medium (DMEM; Thermo Fisher, PN 31600034) with 10% fetal bovine serum supplemented with 3.5 g of glucose and 1.5 g of sodium bicarbonate at 37°C and 5% CO<sub>2</sub>. Chinese hamster ovarian (CHO) cells were grown in DMEM with 10% fetal bovine serum supplemented with 0.8 g of glucose, 1.5 g of sodium bicarbonate, and 1% NEAA at 37°C and 5% CO<sub>2</sub>. The RCS Fgfr1–4 <italic>null</italic> cells were prepared by Crispr/Cas9-mediated inactivation of <italic>Fgfr1</italic>, <italic>Fgfr2</italic>, <italic>Fgfr3</italic>, and <italic>Fgfr4</italic> loci (<xref ref-type="bibr" rid="bib37">Kimura et al., 2021</xref>). RCS<sup>Fgfr1</sup> cells were prepared by Crispr/Cas9-mediated inactivation of <italic>Fgfr2</italic> in <italic>Fgfr3/4</italic> double knock-out RCS cells (a gift from Carmine Settembre).</p></sec><sec id="s4-2"><title>FIF spectrometry</title><p>HEK 293T cells, stably transfected with FGFR1-YFP, were seeded on collagen-coated, glass-bottom Petri dishes (MatTek, P35GCOL-1.5-14-C) and allowed to grow to ~70% confluency at 37°C and 5% CO<sub>2</sub>. Cells were grown in DMEM with 10% fetal bovine serum, supplemented with 3.5 g of glucose and 1.5 g of sodium bicarbonate. Cells were rinsed with 70% swelling media (1:9 serum-free media, diH<sub>2</sub>O, 25 mM HEPES), and then swelled in 70% swelling media plus ligand for ~5 min before imaging. This treatment minimizes the ruffles in the plasma membrane and prevents endocytosis (<xref ref-type="bibr" rid="bib69">Rauch and Farge, 2000</xref>; <xref ref-type="bibr" rid="bib83">Sinha et al., 2011</xref>).</p><p>The plasma membranes facing the support were imaged on a TCS SP8 confocal microscope using a photon counting detector. Images were analyzed using the FIF software (<xref ref-type="bibr" rid="bib86">Stoneman et al., 2019</xref>). Briefly, the membrane was divided into 15×15 pixel regions of interest and the molecular brightness, ε, of each region was calculated as:<disp-formula id="equ1"><mml:math id="m1"><mml:mi>ε</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mfenced open="⟨" close="⟩" separators="|"><mml:mrow><mml:mi>I</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:math></disp-formula></p><p>where 〈I〉 is the center of the Gaussian distribution and σ<sup>2</sup> is the variance in each segment. The brightness values from thousands of regions of interest were binned and histogrammed. The histograms were then normalized to 1.</p><p>Since the molecular brightness distribution is log-normal, the values of log(brightness) were histogrammed and fit to a Gaussian function:<disp-formula id="equ2"> <mml:math id="m2"><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>i</mml:mi><mml:mi>z</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mi>a</mml:mi><mml:mo>∗</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mfrac><mml:mrow><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>θ</mml:mi><mml:mo>−</mml:mo><mml:mi>m</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mi>s</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula></p><p>Here, θ represents the log of the brightness, m is the mean of the Gaussian, s is the standard deviation of the Gaussian, and a is a constant. The best-fit Gaussian parameters are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</p><p>In order to determine whether the distributions were the same or different, a Z-statistics analysis was used, where the Z value is given by:<disp-formula id="equ3"> <mml:math id="m3"><mml:mi>Z</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msqrt><mml:msubsup><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>q</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:msqrt></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Here, m<sub>1</sub> and m<sub>2</sub> represent the two means of the Gaussians being compared, and q<sub>1</sub> and q<sub>2</sub> are the standard deviations for each Gaussian divided by the square root of the number of cells analyzed. A minimum of 100 cells were analyzed for each data set.</p><p>A Z value of less than 2 means that the data sets are within 2 standard deviations of the mean and are therefore the same, while a Z value greater than 2 means that the two data sets are different (<xref ref-type="bibr" rid="bib2">Anderson et al., 2001</xref>). Calculated Z values can be found in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>.</p></sec><sec id="s4-3"><title>Western blots</title><p>HEK 293T cells stably expressing FGFR1 were seeded in equal volumes into 12-well plates and allowed to grow to ~70–90% confluency, while changing the media after 48 hr. The full media was aspirated and replaced with DMEM without fetal bovine serum. Varying amounts of ligands (R&amp;D Systems; FGF4, #235-F4-025; FGF8, #423-F8-025, and FGF9, # 273-F9-025) were added to each well to create a ligand concentration gradient. Cells were incubated with the ligands at 37°C and 5% CO<sub>2</sub> for 20 min and then immediately placed on ice. Media was aspirated and cells were immediately lysed with 2× Laemmli Buffer (Bio-Rad 1610737)+5% BME. Lysates were moved to clean Eppendorf tubes and vortexed for 10 s intervals six times over the course of 5–10 min, staying on ice in the interim. Lysates were centrifuged, boiled at 98°C for 10 min, and then immediately placed on ice until cool. Lysates were then centrifuged again and stored at –20°C for later use. Lysates were thawed on ice and vortexed immediately prior to loading onto gel. Gels were run on ice at 140 V for 3 hr using Bio-Rad Mini-Protean TGX precast gels in 1× Tris/Gly/SDS running buffer (Bio-Rad #1610732). Gels were then equilibrated with transfer buffer (Bio-Rad #1610734) supplemented with 20% methanol for 10 min. Transfer was performed using the Iblot 2 Gel Transfer Device (Thermo Fisher #IB21001) and nitrocellulose packs (Thermo Fisher IB23001). Nitrocellulose membranes were removed and replaced with PVDF membranes (Bio-Rad #1620177) that had been activated in 100% methanol, all other steps were as prescribed by Thermo Fisher. Transfers were done at 25 V for 7 min. Following transfer, membranes were immediately trimmed and placed in either 5% non-fat milk or 5% BSA in 1× TBS supplemented with 1% Tween (Sigma #P1379) (TBST) depending on the primary antibody used. Blocking was accomplished on a rocker for 1–2 hr at room temperature. Membranes were rinsed 2× with TBST and then primary antibody was added at a 1:1000 dilution. Primary antibodies (Cell Signaling: anti-Y653/654 #3471S, anti-FGFR1 #9740S, anti-pY766 FGFR1, #2544, anti-Actin #3700, anti-pERK1/2 #9101, anti-pFRS2 #3861S, anti-pPLCγ #2821S, anti-PLCγ #2822S, anti-Vinculin #13901; Santa Cruz: anti-FGFR2 #sc122; Cedarlane: anti-collagen 2 #CL50241AP; Invitrogen: anti-V5 #46-0705) were incubated with the membrane overnight at 4°C on a rocker. The primary antibody was removed and the membrane was washed with TBST three times for 5–15 min. The secondary antibody (Promega: anti-rabbit #W4011; Sigma: anti-mouse #A6782) was added at a dilution of 1:10,000 and allowed to incubate on a rocker at room temperature for 1–2 hr. The secondary antibody was removed and the membrane was washed with TBST 3× for 5–15 min. The membrane was incubated with chemiluminescent solution (Thermo Fisher Scientific West Femto Supersignal, #1706435) and imaged on a Bio-Rad Gel-Doc XRS+.</p><p>Blot images were stored digitally. The intensity of each band was quantified using ImageJ.</p></sec><sec id="s4-4"><title>Scaling of phosphorylation western blot data</title><p>To identify and quantify bias, the phosphorylation dose-response curves for the three ligands have to be globally scaled such that the efficacy of the full agonist is set to 1, and the efficacies of the partial agonist are scaled accordingly. Below, we present the protocol. Steps 1 through 3 are used in the literature to scale the individual dose-response curves. Steps 4 through 6 implement the global scaling.</p><list list-type="order"><list-item><p>Collect at least three independent dose-response curves for each ligand. Each dose response is acquired using one gel.</p></list-item><list-item><p>Scale each dose-response curve so max is 1. In other words, set the band intensity for the sample with the highest band intensity to 1.</p></list-item><list-item><p>Average the dose-response curves, and reset the maximum value to 1 if needed.</p></list-item><list-item><p>For each ligand, re-run three of the samples with intensity 1 on a gel. This is the so-called ‘gluing gel’. This gel includes three samples for each ligand, so nine total (see <xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p></list-item><list-item><p>Average the three intensities for each ligand. Identify the ligand that yielded the highest average intensity. Rescale the three averages, such that this highest intensity is set to 1.</p></list-item><list-item><p>Multiply the averaged dose-response curves by the respective global scaling coefficients to obtain the globally scaled dose-response curves.</p></list-item></list></sec><sec id="s4-5"><title>Scaling of FGFR1 and collagen abundance gels</title><p>In this case, the band intensities at zero ligand are the highest and they are set to 1; the rest are scaled accordingly. Results from at least three independent samples are averaged. Then, 1 is subtracted from all the data and the sign is inverted to obtain loss of abundance dose-response curves.</p></sec><sec id="s4-6"><title>Fitting of dose-response curves</title><p>The scaled dose-response curves were fitted to a rectangular hyperbolic (Hill equation with n=1) given by:<disp-formula id="equ4"> <label>(1)</label><mml:math id="m4"><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>p</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:mfenced><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi>x</mml:mi></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Here, [x] represents the concentration of ligand, while E<sub>top</sub> corresponds to the plateau at high ligand concentrations and EC<sub>50</sub> corresponds to the ligand concentration value at which 50% of E<sub>top</sub> is achieved.</p><p>To fit the data to <xref ref-type="disp-formula" rid="equ4">Equation 1</xref>, we truncated each dose-response curve at the highest ligand concentration that is within 10% of the maximum y value. This took into account that the average y value error is between 5% and 10%. The data was fit in Mathematica with the NonlinearModelFit function using the Levenberg-Marquardt minimization method, while allowing for a maximum of 100,000 iterations. The errors of the fit were weighted as the inverse of the square of the error.</p></sec><sec id="s4-7"><title>Calculation of bias coefficients</title><p>To calculate bias coefficients, FGF8 was chosen as the reference ligand. Bias coefficients, β, for FGF4 and FGF9 were calculated using <xref ref-type="disp-formula" rid="equ5">Equation 2</xref>.<disp-formula id="equ5"> <label>(2)</label><mml:math id="m5"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mn>4</mml:mn><mml:mo>,</mml:mo><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>∗</mml:mo><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>4</mml:mn><mml:mo>,</mml:mo><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mfrac><mml:mo>∗</mml:mo><mml:mfrac><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>50.2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Standard errors of β were calculated using the standard errors of EC<sub>50</sub> and E<sub>top</sub>, as determined from the fit in <xref ref-type="disp-formula" rid="equ4">Equation 1</xref>, using the functional approach for multi-variable functions (<xref ref-type="bibr" rid="bib28">Hughes and Hase, 2010</xref>).</p><p>To compare bias coefficients for the three ligands and determine statistical significance in a three-way comparison, we follow the protocol in <xref ref-type="bibr" rid="bib31">Karl et al., 2020</xref>, re-writing <xref ref-type="disp-formula" rid="equ5">Equation 2</xref> as:<disp-formula id="equ6"> <label>(3)</label><mml:math id="m6"><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>4,9</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi><mml:mi>`</mml:mi></mml:mrow><mml:mrow><mml:mn>4,9</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi><mml:mi>`</mml:mi></mml:mrow><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub></mml:math></disp-formula></p><p>where β’ is calculated in <xref ref-type="disp-formula" rid="equ7">Equation 4</xref>.<disp-formula id="equ7"> <label>(4)</label><mml:math id="m7"><mml:mrow><mml:msubsup><mml:mi>β</mml:mi><mml:mrow><mml:mn>4</mml:mn><mml:mo>,</mml:mo><mml:mn>8</mml:mn><mml:mo>,</mml:mo><mml:mn>9</mml:mn></mml:mrow><mml:mo>′</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>∗</mml:mo><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:msub><mml:mi>E</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>4</mml:mn><mml:mo>,</mml:mo><mml:mn>8</mml:mn><mml:mo>,</mml:mo><mml:mn>9</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula></p><p>Standard errors of β’ were calculated using the standard errors of EC<sub>50</sub> and E<sub>top</sub> using the functional approach for multi-variable functions (<xref ref-type="bibr" rid="bib28">Hughes and Hase, 2010</xref>). The β’ values and their corresponding errors are reported in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</p><p>Statistical significance of the differences between β’ values were calculated with a one-way ANOVA using the multi-variable analysis option in Prism. The data that were inputted were the mean, SEM, and n, the number of points contributing to the fit. In <xref ref-type="fig" rid="fig3">Figure 3</xref>, n=9 for FGF4, n=10 for FGF8, and n=7 for FGF9. The calculated p-values are shown in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>.</p></sec><sec id="s4-8"><title>FRET measurements</title><p>CHO cells were seeded into tissue culture-treated six-well plates at a density of 2*10<sup>4</sup> cells/well. 24 hr later, the cells were co-transfected with FGFR1-ECTM-eYFP and FGFR1-ECTM-mCherry using Fugene HD (Promega # E2311) according to the manufacturer’s instructions. ECTM constructs included the entire EC domain and TM domain up to residue 402, followed by a (GGS)<sub>5</sub> flexible linker and the fluorophore (<xref ref-type="bibr" rid="bib75">Sarabipour and Hristova, 2016</xref>). The amount of DNA as well as the donor to acceptor ratio of the DNA added was varied to achieve a wide range of donor and acceptor expressions (<xref ref-type="bibr" rid="bib73">Sarabipour et al., 2015</xref>).</p><p>Cells were vesiculated ~24 hr after transfection as described previously (<xref ref-type="bibr" rid="bib11">Del Piccolo et al., 2012</xref>). Briefly, the cells were rinsed 2 × with 30% PBS and then incubated for 13 hr at 37°C and 5% CO<sub>2</sub> in a chloride salt buffer. Vesicles were then transferred to four-well glass-bottomed chamber slides for imaging on a Nikon confocal microscope with a 60× objective to capture images of the equatorial cross-sections of the vesicles in three channels: donor (eYFP), acceptor (mCherry), and FRET (<xref ref-type="bibr" rid="bib74">Sarabipour et al., 2016</xref>). FRET was measured following the QI-FRET protocol (<xref ref-type="bibr" rid="bib73">Sarabipour et al., 2015</xref>; <xref ref-type="bibr" rid="bib7">Chen et al., 2010a</xref>), which yields the donor concentration, the acceptor concentration, and the FRET efficiency in each vesicle. The microscope was calibrated using solutions of fluorescent protein of known concentration, so that the fluorescence intensity could be directly correlated to fluorophore concentration.</p><p>In the case of constitutive dimers at high ligand concentration, when FRET does not depend on receptor concentration, the measured FRET and the intrinsic FRET are connected as follows <xref ref-type="bibr" rid="bib38">King et al., 2016</xref>:<disp-formula id="equ8"><label>(5)</label><mml:math id="m8"><mml:mrow><mml:mrow><mml:mover><mml:mi>E</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mi>E</mml:mi><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>Here, x<sub>A</sub> is the acceptor fraction, which is measured in each vesicle, along with the FRET efficiency, E. <xref ref-type="disp-formula" rid="equ8">Equation 5</xref> allows us to directly determine the value of the intrinsic FRET, Ẽ, in each vesicle. The dependence of the intrinsic FRET, Ẽ, on the distance between the fluorescent proteins in the dimer, d, is given by <xref ref-type="disp-formula" rid="equ1">Equation 6</xref>.<disp-formula id="equ9"><label>(6)</label><mml:math id="m9"><mml:mrow><mml:mrow><mml:mover><mml:mi>E</mml:mi><mml:mo stretchy="false">~</mml:mo></mml:mover></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mi>d</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mi>O</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>Here, R<sub>o</sub> is the Förster radius of the FRET pair. For eYFP and mCherry, R<sub>0</sub> is 53.1 Å (<xref ref-type="bibr" rid="bib7">Chen et al., 2010a</xref>; <xref ref-type="bibr" rid="bib8">Chen et al., 2010b</xref>). This equation assumes free rotation of the fluorescent proteins. This assumption can be justified because the fluorescent proteins are attached via flexible linkers.</p></sec><sec id="s4-9"><title>Ligand-induced FGFR1 removal from the plasma membrane</title><p>FGFR1 downregulation in the plasma membrane was assayed by measuring the FGFR1 membrane concentration before and 2 min after ligand addition. FGFR1-YFP in the plasma membrane in contact with the substrate was imaged in a TCS SP8 confocal microscope, and FGFR1-YFP fluorescence per unit membrane area was quantified. HEK 293T cells, stably transfected with FGFR1-YFP, were seeded on collagen-coated, glass-bottom Petri dishes (MatTek, P35GCOL-1.5-14-C) and allowed to grow to ~70% confluency at 37°C and 5% CO<sub>2</sub>. Cells were rinsed with serum-free media and exposed to 130 nM of either FGF8 or FGF9 or no ligand and incubated at 37°C and 5% CO<sub>2</sub> for 2 min. The cells were fixed in a solution of 4% formaldehyde in PBS for 20 min at room temperature. Samples were stored at 4°C prior to imaging. A minimum of 100 cells per condition were imaged, in three independent experiments. The receptor concentration in the membrane of each cell was quantified using the FIF software (<xref ref-type="bibr" rid="bib86">Stoneman et al., 2019</xref>), and results for all analyzed cells per condition were averaged.</p></sec><sec id="s4-10"><title>Viability assays</title><p>Cell viability was monitored using a MTT Cell Proliferation Assay Kit (Cell BioLabs, #CBS-252). HEK 293T cells, stably transfected with FGFR1-YFP, were seeded in 96-well plates and allowed to grow to ~70% confluency. Media was aspirated and replaced with serum-free media and with varying concentrations of ligand. After ligand addition, cells were kept at 37°C and 5% CO<sub>2</sub> for 6 days. Viability was measured according to the manufacturer’s protocol. Briefly, CytoSelect MTT Cell Proliferation Assay Reagent was added directly to the cell media. After 3 hr of incubation at 37°C and 5% CO<sub>2</sub>, the cells were lysed with detergent and kept at room temperature for 2 hr. The absorbance was measured on a Synergy H4 plate reader at 555 nm.</p></sec><sec id="s4-11"><title>Apoptosis assays</title><p>Apoptosis was probed using the Bio-Rad Magic Red Caspase 3-7 kit (Bio-Rad, ICT 935). HEK 293T cells stably expressing FGFR1-YFP were seeded in 96-well plates and allowed to grow to ~70% confluency. Media was aspirated and replaced with serum-free media with the Magic Red staining solution and varying concentrations of ligand. After ligand treatment the cells were placed in the incubator at 37°C and 5% CO<sub>2</sub> for 6 days. The fluorescence of the cleaved substrate (Cresyl Violet) was measured on a Synergy H4 plate reader. The excitation wavelength was 592 nm. Emission was measured at 628 nm.</p></sec><sec id="s4-12"><title>ERK activation, cell count, and collagen expression experiments in RCS<sup>Fgfr1</sup> cells</title><p>The pKrox(MapERK)d1EGFP reporter was stably expressed in RCS<sup>Fgfr1</sup> cells using the piggyBac transposase. Activation of the pKrox(MapERK)d1EGFP reporter in RCS<sup>Fgfr1</sup> cells was measured using an automated incubation microscope BioStation CT (Nikon, Tokyo, Japan). Phase contrast and fluorescence signal images were automatically acquired every 1 hr during a 48 hr time period. Fluorescence of the reporter was then processed and analyzed with the Nikon BioStation CT software.</p><p>For the growth arrest assay, the RCS cells were treated with 1 µg/ml heparin and FGF ligands for 3 days. Cell numbers were determined by counting (Beckman-Coulter). For collagen type 2 expression, the RCS cells were treated with 1 µg/ml heparin and FGF ligands for 48 hr. Collagen type 2 expression was measured by western blotting.</p></sec><sec id="s4-13"><title>Materials availability statement</title><p>Cell lines created for this work are available upon request.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Investigation</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Funding acquisition, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Funding acquisition, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Best-fit Gaussian parameters for the different log(brightness) distributions.</title></caption><media xlink:href="elife-88144-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Calculated Z values from the Gaussian fit parameters in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>.</title></caption><media xlink:href="elife-88144-supp2-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>β’<sub>4</sub>, β’<sub>8</sub>, and β’<sub>9</sub> values calculated for each response using <xref ref-type="disp-formula" rid="equ7">Equation 4</xref>.</title></caption><media xlink:href="elife-88144-supp3-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Comparison of β’<sub>4</sub>, β’<sub>8</sub>, and β’<sub>9</sub> values from <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>.</title></caption><media xlink:href="elife-88144-supp4-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Summary of results shown in <xref ref-type="fig" rid="fig5">Figure 5A–C</xref>.</title></caption><media xlink:href="elife-88144-supp5-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-88144-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data are included in the manuscript. All source data have been provided.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Marie Tesarova for excellent technical assistance and Carmine Settembre, Telethon Institute of Genetics and Medicine, Italy, for providing <italic>Fgf3/4</italic> double knock-out RCS cells. The work was supported by NIH GM068619 and NSF MCB 2106031 to KH. PK is supported by the Czech Science Foundation (GA19-20123S, GF21-26400K); Ministry of Education, Youth and Sports of the Czech Republic (INTER-ACTION LUAUS23295); Grant Agency of Masaryk University (MUNI/G/1771/2020); National Institute for Cancer Research (Programme EXCELES, ID Project No. LX22NPO5102) - Funded by the European Union - Next Generation EU. BF is supported by the Agency for Healthcare Research of the Czech Republic (NU21-06-00512).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>F</given-names></name><name><surname>Zapata-Mercado</surname><given-names>E</given-names></name><name><surname>Rahman</surname><given-names>S</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The biased ligands NGF and NT-3 differentially stabilize Trk-A Dimers</article-title><source>Biophysical Journal</source><volume>120</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2020.11.2262</pub-id><pub-id pub-id-type="pmid">33285113</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>D</given-names></name><name><surname>Sweeney</surname><given-names>DJ</given-names></name><name><surname>Williams</surname><given-names>TA</given-names></name><name><surname>Camm</surname><given-names>JD</given-names></name><name><surname>Cochran</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><source>Modern Business Statistics with Microsoft Excel</source><publisher-name>Cengage</publisher-name></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bocharov</surname><given-names>EV</given-names></name><name><surname>Mineev</surname><given-names>KS</given-names></name><name><surname>Pavlov</surname><given-names>KV</given-names></name><name><surname>Akimov</surname><given-names>SA</given-names></name><name><surname>Kuznetsov</surname><given-names>AS</given-names></name><name><surname>Efremov</surname><given-names>RG</given-names></name><name><surname>Arseniev</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Helix-helix interactions in membrane domains of bitopic proteins: specificity and role of lipid environment</article-title><source>Biochimica et Biophysica Acta</source><volume>1859</volume><fpage>561</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2016.10.024</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Browne</surname><given-names>BC</given-names></name><name><surname>O’Brien</surname><given-names>N</given-names></name><name><surname>Duffy</surname><given-names>MJ</given-names></name><name><surname>Crown</surname><given-names>J</given-names></name><name><surname>O’Donovan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>HER-2 signaling and inhibition in breast cancer</article-title><source>Current Cancer Drug Targets</source><volume>9</volume><fpage>419</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.2174/156800909788166484</pub-id><pub-id pub-id-type="pmid">19442060</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchtova</surname><given-names>M</given-names></name><name><surname>Chaloupkova</surname><given-names>R</given-names></name><name><surname>Zakrzewska</surname><given-names>M</given-names></name><name><surname>Vesela</surname><given-names>I</given-names></name><name><surname>Cela</surname><given-names>P</given-names></name><name><surname>Barathova</surname><given-names>J</given-names></name><name><surname>Gudernova</surname><given-names>I</given-names></name><name><surname>Zajickova</surname><given-names>R</given-names></name><name><surname>Trantirek</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Kostas</surname><given-names>M</given-names></name><name><surname>Otlewski</surname><given-names>J</given-names></name><name><surname>Damborsky</surname><given-names>J</given-names></name><name><surname>Kozubik</surname><given-names>A</given-names></name><name><surname>Wiedlocha</surname><given-names>A</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Instability restricts signaling of multiple fibroblast growth factors</article-title><source>Cellular and Molecular Life Sciences</source><volume>72</volume><fpage>2445</fpage><lpage>2459</lpage><pub-id pub-id-type="doi">10.1007/s00018-015-1856-8</pub-id><pub-id pub-id-type="pmid">25854632</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgar</surname><given-names>HR</given-names></name><name><surname>Burns</surname><given-names>HD</given-names></name><name><surname>Elsden</surname><given-names>JL</given-names></name><name><surname>Lalioti</surname><given-names>MD</given-names></name><name><surname>Heath</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Association of the signaling adaptor FRS2 with fibroblast growth factor receptor 1 (Fgfr1) is mediated by alternative splicing of the juxtamembrane domain</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>4018</fpage><lpage>4023</lpage><pub-id pub-id-type="doi">10.1074/jbc.M107785200</pub-id><pub-id pub-id-type="pmid">11729184</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LR</given-names></name><name><surname>Novicky</surname><given-names>L</given-names></name><name><surname>Merzlyakov</surname><given-names>M</given-names></name><name><surname>Hristov</surname><given-names>T</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010a</year><article-title>Measuring the energetics of membrane protein dimerization in mammalian membranes</article-title><source>Journal of the American Chemical Society</source><volume>132</volume><fpage>3628</fpage><lpage>3635</lpage><pub-id pub-id-type="doi">10.1021/ja910692u</pub-id><pub-id pub-id-type="pmid">20158179</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Placone</surname><given-names>J</given-names></name><name><surname>Novicky</surname><given-names>L</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010b</year><article-title>The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization</article-title><source>Science Signaling</source><volume>3</volume><elocation-id>ra86</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2001195</pub-id><pub-id pub-id-type="pmid">21119106</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correll</surname><given-names>CC</given-names></name><name><surname>McKittrick</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Biased ligand modulation of seven transmembrane receptors (7TMRs): functional implications for drug discovery</article-title><source>Journal of Medicinal Chemistry</source><volume>57</volume><fpage>6887</fpage><lpage>6896</lpage><pub-id pub-id-type="doi">10.1021/jm401677g</pub-id><pub-id pub-id-type="pmid">24697360</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dailey</surname><given-names>L</given-names></name><name><surname>Laplantine</surname><given-names>E</given-names></name><name><surname>Priore</surname><given-names>R</given-names></name><name><surname>Basilico</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation</article-title><source>The Journal of Cell Biology</source><volume>161</volume><fpage>1053</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1083/jcb.200302075</pub-id><pub-id pub-id-type="pmid">12821644</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Piccolo</surname><given-names>N</given-names></name><name><surname>Placone</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Agudelo</surname><given-names>SC</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Production of plasma membrane vesicles with chloride salts and their utility as a cell membrane mimetic for biophysical characterization of membrane protein interactions</article-title><source>Analytical Chemistry</source><volume>84</volume><fpage>8650</fpage><lpage>8655</lpage><pub-id pub-id-type="doi">10.1021/ac301776j</pub-id><pub-id pub-id-type="pmid">22985263</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Digman</surname><given-names>MA</given-names></name><name><surname>Gratton</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Scanning image correlation spectroscopy</article-title><source>BioEssays</source><volume>34</volume><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1002/bies.201100118</pub-id><pub-id pub-id-type="pmid">22415853</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doerner</surname><given-names>A</given-names></name><name><surname>Scheck</surname><given-names>R</given-names></name><name><surname>Schepartz</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Growth factor identity is encoded by discrete coiled-coil rotamers in the EGFR Juxtamembrane region</article-title><source>Chemistry &amp; Biology</source><volume>22</volume><fpage>776</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2015.05.008</pub-id><pub-id pub-id-type="pmid">26091170</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehlert</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Analysis of biased agonism</article-title><source>Progress in Molecular Biology and Translational Science</source><volume>160</volume><fpage>63</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/bs.pmbts.2018.08.001</pub-id><pub-id pub-id-type="pmid">30470293</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eswarakumar</surname><given-names>VP</given-names></name><name><surname>Lax</surname><given-names>I</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cellular signaling by fibroblast growth factor receptors</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>16</volume><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2005.01.001</pub-id><pub-id pub-id-type="pmid">15863030</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fafilek</surname><given-names>B</given-names></name><name><surname>Hampl</surname><given-names>M</given-names></name><name><surname>Ricankova</surname><given-names>N</given-names></name><name><surname>Vesela</surname><given-names>I</given-names></name><name><surname>Balek</surname><given-names>L</given-names></name><name><surname>Kunova Bosakova</surname><given-names>M</given-names></name><name><surname>Gudernova</surname><given-names>I</given-names></name><name><surname>Varecha</surname><given-names>M</given-names></name><name><surname>Buchtova</surname><given-names>M</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Statins do not inhibit the FGFR signaling in chondrocytes</article-title><source>Osteoarthritis and Cartilage</source><volume>25</volume><fpage>1522</fpage><lpage>1530</lpage><pub-id pub-id-type="doi">10.1016/j.joca.2017.05.014</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fafilek</surname><given-names>B</given-names></name><name><surname>Balek</surname><given-names>L</given-names></name><name><surname>Bosakova</surname><given-names>MK</given-names></name><name><surname>Varecha</surname><given-names>M</given-names></name><name><surname>Nita</surname><given-names>A</given-names></name><name><surname>Gregor</surname><given-names>T</given-names></name><name><surname>Gudernova</surname><given-names>I</given-names></name><name><surname>Krenova</surname><given-names>J</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Piskacek</surname><given-names>M</given-names></name><name><surname>Jonatova</surname><given-names>L</given-names></name><name><surname>Cernohorsky</surname><given-names>NH</given-names></name><name><surname>Zieba</surname><given-names>JT</given-names></name><name><surname>Kostas</surname><given-names>M</given-names></name><name><surname>Haugsten</surname><given-names>EM</given-names></name><name><surname>Wesche</surname><given-names>J</given-names></name><name><surname>Erneux</surname><given-names>C</given-names></name><name><surname>Trantirek</surname><given-names>L</given-names></name><name><surname>Krakow</surname><given-names>D</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases</article-title><source>Science Signaling</source><volume>11</volume><elocation-id>eaap8608</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aap8608</pub-id><pub-id pub-id-type="pmid">30228226</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freed</surname><given-names>DM</given-names></name><name><surname>Bessman</surname><given-names>NJ</given-names></name><name><surname>Kiyatkin</surname><given-names>A</given-names></name><name><surname>Salazar-Cavazos</surname><given-names>E</given-names></name><name><surname>Byrne</surname><given-names>PO</given-names></name><name><surname>Moore</surname><given-names>JO</given-names></name><name><surname>Valley</surname><given-names>CC</given-names></name><name><surname>Ferguson</surname><given-names>KM</given-names></name><name><surname>Leahy</surname><given-names>DJ</given-names></name><name><surname>Lidke</surname><given-names>DS</given-names></name><name><surname>Lemmon</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics</article-title><source>Cell</source><volume>171</volume><fpage>683</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.09.017</pub-id><pub-id pub-id-type="pmid">28988771</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furdui</surname><given-names>CM</given-names></name><name><surname>Lew</surname><given-names>ED</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction</article-title><source>Molecular Cell</source><volume>21</volume><fpage>711</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2006.01.022</pub-id><pub-id pub-id-type="pmid">16507368</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleizes</surname><given-names>PE</given-names></name><name><surname>Noaillac-Depeyre</surname><given-names>J</given-names></name><name><surname>Amalric</surname><given-names>F</given-names></name><name><surname>Gas</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Basic fibroblast growth factor (FGF-2) internalization through the heparan sulfate proteoglycans-mediated pathway: an ultrastructural approach</article-title><source>European Journal of Cell Biology</source><volume>66</volume><fpage>47</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">7750519</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goetz</surname><given-names>R</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Exploring mechanisms of FGF signalling through the lens of structural biology</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>14</volume><fpage>166</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1038/nrm3528</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Soler</surname><given-names>M</given-names></name><name><surname>Petersen Gehring</surname><given-names>M</given-names></name><name><surname>Lechtenberg</surname><given-names>BC</given-names></name><name><surname>Zapata-Mercado</surname><given-names>E</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name><name><surname>Pasquale</surname><given-names>EB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>8791</fpage><lpage>8805</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.008213</pub-id><pub-id pub-id-type="pmid">31015204</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins</article-title><source>Cancer Science</source><volume>99</volume><fpage>1319</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2008.00840.x</pub-id><pub-id pub-id-type="pmid">18452557</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudernova</surname><given-names>I</given-names></name><name><surname>Foldynova-Trantirkova</surname><given-names>S</given-names></name><name><surname>Ghannamova</surname><given-names>BE</given-names></name><name><surname>Fafilek</surname><given-names>B</given-names></name><name><surname>Varecha</surname><given-names>M</given-names></name><name><surname>Balek</surname><given-names>L</given-names></name><name><surname>Hruba</surname><given-names>E</given-names></name><name><surname>Jonatova</surname><given-names>L</given-names></name><name><surname>Jelinkova</surname><given-names>I</given-names></name><name><surname>Kunova Bosakova</surname><given-names>M</given-names></name><name><surname>Trantirek</surname><given-names>L</given-names></name><name><surname>Mayer</surname><given-names>J</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>One reporter for in-cell activity profiling of majority of protein kinase oncogenes</article-title><source>eLife</source><volume>6</volume><elocation-id>e21536</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.21536</pub-id><pub-id pub-id-type="pmid">28199182</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gundry</surname><given-names>J</given-names></name><name><surname>Glenn</surname><given-names>R</given-names></name><name><surname>Alagesan</surname><given-names>P</given-names></name><name><surname>Rajagopal</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A practical guide to approaching biased agonism at g protein coupled receptors</article-title><source>Frontiers in Neuroscience</source><volume>11</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2017.00017</pub-id><pub-id pub-id-type="pmid">28174517</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadari</surname><given-names>YR</given-names></name><name><surname>Kouhara</surname><given-names>H</given-names></name><name><surname>Lax</surname><given-names>I</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation</article-title><source>Molecular and Cellular Biology</source><volume>18</volume><fpage>3966</fpage><lpage>3973</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.7.3966</pub-id><pub-id pub-id-type="pmid">9632781</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Bharill</surname><given-names>S</given-names></name><name><surname>Karandur</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>SM</given-names></name><name><surname>Marita</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Kaliszewski</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>AW</given-names></name><name><surname>Isacoff</surname><given-names>EY</given-names></name><name><surname>Kuriyan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Molecular basis for multimerization in the activation of the epidermal growth factor receptor</article-title><source>eLife</source><volume>5</volume><elocation-id>e14107</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.14107</pub-id><pub-id pub-id-type="pmid">27017828</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>IG</given-names></name><name><surname>Hase</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><source>Measurements and their uncertainties: a practical guide to modern error analysis</source><publisher-name>Oxford University Press</publisher-name></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahsai</surname><given-names>AW</given-names></name><name><surname>Xiao</surname><given-names>K</given-names></name><name><surname>Rajagopal</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>S</given-names></name><name><surname>Shukla</surname><given-names>AK</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Oas</surname><given-names>TG</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Multiple ligand-specific conformations of the β2-adrenergic receptor</article-title><source>Nature Chemical Biology</source><volume>7</volume><fpage>692</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1038/nchembio.634</pub-id><pub-id pub-id-type="pmid">21857662</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamemura</surname><given-names>N</given-names></name><name><surname>Murakami</surname><given-names>S</given-names></name><name><surname>Komatsu</surname><given-names>H</given-names></name><name><surname>Sawanoi</surname><given-names>M</given-names></name><name><surname>Miyamoto</surname><given-names>K</given-names></name><name><surname>Ishidoh</surname><given-names>K</given-names></name><name><surname>Kishimoto</surname><given-names>K</given-names></name><name><surname>Tsuji</surname><given-names>A</given-names></name><name><surname>Yuasa</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Type II cGMP-dependent protein kinase negatively regulates fibroblast growth factor signaling by phosphorylating Raf-1 at serine 43 in rat chondrosarcoma cells</article-title><source>Biochemical and Biophysical Research Communications</source><volume>483</volume><fpage>82</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.01.001</pub-id><pub-id pub-id-type="pmid">28057484</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karl</surname><given-names>K</given-names></name><name><surname>Paul</surname><given-names>MD</given-names></name><name><surname>Pasquale</surname><given-names>EB</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Ligand bias in receptor tyrosine kinase signaling</article-title><source>The Journal of Biological Chemistry</source><volume>295</volume><fpage>18494</fpage><lpage>18507</lpage><pub-id pub-id-type="doi">10.1074/jbc.REV120.015190</pub-id><pub-id pub-id-type="pmid">33122191</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karl</surname><given-names>K</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Pondering the mechanism of receptor tyrosine kinase activation: The case for ligand-specific dimer microstate ensembles</article-title><source>Current Opinion in Structural Biology</source><volume>71</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2021.07.003</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenakin</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Functional selectivity and biased receptor signaling</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>336</volume><fpage>296</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1124/jpet.110.173948</pub-id><pub-id pub-id-type="pmid">21030484</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenakin</surname><given-names>T</given-names></name><name><surname>Christopoulos</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Measurements of ligand bias and functional affinity</article-title><source>Nature Reviews. Drug Discovery</source><volume>12</volume><elocation-id>483</elocation-id><pub-id pub-id-type="doi">10.1038/nrd3954-c2</pub-id><pub-id pub-id-type="pmid">23681003</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenakin</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Measurement of receptor signaling bias</article-title><source>Current Protocols in Pharmacology</source><volume>74</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1002/cpph.11</pub-id><pub-id pub-id-type="pmid">27636109</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenakin</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Biased receptor signaling in drug discovery</article-title><source>Pharmacological Reviews</source><volume>71</volume><fpage>267</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1124/pr.118.016790</pub-id><pub-id pub-id-type="pmid">30914442</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Bosakova</surname><given-names>M</given-names></name><name><surname>Nonaka</surname><given-names>Y</given-names></name><name><surname>Hruba</surname><given-names>E</given-names></name><name><surname>Yasuda</surname><given-names>K</given-names></name><name><surname>Futakawa</surname><given-names>S</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Fafilek</surname><given-names>B</given-names></name><name><surname>Gregor</surname><given-names>T</given-names></name><name><surname>Abraham</surname><given-names>SP</given-names></name><name><surname>Gomolkova</surname><given-names>R</given-names></name><name><surname>Belaskova</surname><given-names>S</given-names></name><name><surname>Pesl</surname><given-names>M</given-names></name><name><surname>Csukasi</surname><given-names>F</given-names></name><name><surname>Duran</surname><given-names>I</given-names></name><name><surname>Fujiwara</surname><given-names>M</given-names></name><name><surname>Kavkova</surname><given-names>M</given-names></name><name><surname>Zikmund</surname><given-names>T</given-names></name><name><surname>Kaiser</surname><given-names>J</given-names></name><name><surname>Buchtova</surname><given-names>M</given-names></name><name><surname>Krakow</surname><given-names>D</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Ozono</surname><given-names>K</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>An RNA aptamer restores defective bone growth in FGFR3-related skeletal dysplasia in mice</article-title><source>Science Translational Medicine</source><volume>13</volume><elocation-id>aba4226</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aba4226</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>C</given-names></name><name><surname>Stoneman</surname><given-names>M</given-names></name><name><surname>Raicu</surname><given-names>V</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fully quantified spectral imaging reveals in vivo membrane protein interactions</article-title><source>Integrative Biology</source><volume>8</volume><fpage>216</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1039/c5ib00202h</pub-id><pub-id pub-id-type="pmid">26787445</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiyatkin</surname><given-names>A</given-names></name><name><surname>van Alderwerelt van Rosenburgh</surname><given-names>IK</given-names></name><name><surname>Klein</surname><given-names>DE</given-names></name><name><surname>Lemmon</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics</article-title><source>Science Signaling</source><volume>13</volume><elocation-id>eaaz5267</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaz5267</pub-id><pub-id pub-id-type="pmid">32817373</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolupaeva</surname><given-names>V</given-names></name><name><surname>Daempfling</surname><given-names>L</given-names></name><name><surname>Basilico</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The B55α regulatory subunit of protein phosphatase 2A mediates fibroblast growth factor-induced p107 dephosphorylation and growth arrest in chondrocytes</article-title><source>Molecular and Cellular Biology</source><volume>33</volume><fpage>2865</fpage><lpage>2878</lpage><pub-id pub-id-type="doi">10.1128/MCB.01730-12</pub-id><pub-id pub-id-type="pmid">23716589</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krejci</surname><given-names>P</given-names></name><name><surname>Prochazkova</surname><given-names>J</given-names></name><name><surname>Smutny</surname><given-names>J</given-names></name><name><surname>Chlebova</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>P</given-names></name><name><surname>Aklian</surname><given-names>A</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Kozubik</surname><given-names>A</given-names></name><name><surname>Wilcox</surname><given-names>WR</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence</article-title><source>Bone</source><volume>47</volume><fpage>102</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.bone.2010.03.021</pub-id><pub-id pub-id-type="pmid">20362703</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kufareva</surname><given-names>I</given-names></name><name><surname>Gustavsson</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Stephens</surname><given-names>BS</given-names></name><name><surname>Handel</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>What Do Structures Tell Us About Chemokine Receptor Function and Antagonism?</article-title><source>Annual Review of Biophysics</source><volume>46</volume><fpage>175</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1146/annurev-biophys-051013-022942</pub-id><pub-id pub-id-type="pmid">28532213</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>George</surname><given-names>B</given-names></name><name><surname>Campbell</surname><given-names>MR</given-names></name><name><surname>Verma</surname><given-names>N</given-names></name><name><surname>Paul</surname><given-names>AM</given-names></name><name><surname>Melo-Alvim</surname><given-names>C</given-names></name><name><surname>Ribeiro</surname><given-names>L</given-names></name><name><surname>Pillai</surname><given-names>MR</given-names></name><name><surname>da Costa</surname><given-names>LM</given-names></name><name><surname>Moasser</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>HER family in cancer progression: From discovery to 2020 and beyond</article-title><source>Advances in Cancer Research</source><volume>147</volume><fpage>109</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/bs.acr.2020.04.001</pub-id><pub-id pub-id-type="pmid">32593399</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lax</surname><given-names>I</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Lamothe</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Frost</surname><given-names>A</given-names></name><name><surname>Hawes</surname><given-names>J</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors</article-title><source>Molecular Cell</source><volume>10</volume><fpage>709</fpage><lpage>719</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(02)00689-5</pub-id><pub-id pub-id-type="pmid">12419216</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>X</given-names></name><name><surname>Nilsson</surname><given-names>M</given-names></name><name><surname>Goldman</surname><given-names>J</given-names></name><name><surname>Reck</surname><given-names>M</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Ares</surname><given-names>LP</given-names></name><name><surname>Frimodt-Moller</surname><given-names>B</given-names></name><name><surname>Wolff</surname><given-names>K</given-names></name><name><surname>Visseren-Grul</surname><given-names>C</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name><name><surname>Garon</surname><given-names>EB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-Mutant NSCLC</article-title><source>Journal of Thoracic Oncology</source><volume>16</volume><fpage>205</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.10.006</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmon</surname><given-names>MA</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Cell signaling by receptor tyrosine kinases</article-title><source>Cell</source><volume>141</volume><fpage>1117</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.06.011</pub-id><pub-id pub-id-type="pmid">20602996</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lew</surname><given-names>ED</given-names></name><name><surname>Furdui</surname><given-names>CM</given-names></name><name><surname>Anderson</surname><given-names>KS</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations</article-title><source>Science Signaling</source><volume>2</volume><elocation-id>ra6</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2000021</pub-id><pub-id pub-id-type="pmid">19224897</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>E</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies</article-title><source>Biochemistry</source><volume>45</volume><fpage>6241</fpage><lpage>6251</lpage><pub-id pub-id-type="doi">10.1021/bi060609y</pub-id><pub-id pub-id-type="pmid">16700535</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JJ</given-names></name><name><surname>Horst</surname><given-names>R</given-names></name><name><surname>Katritch</surname><given-names>V</given-names></name><name><surname>Stevens</surname><given-names>RC</given-names></name><name><surname>Wüthrich</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR</article-title><source>Science</source><volume>335</volume><fpage>1106</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1126/science.1215802</pub-id><pub-id pub-id-type="pmid">22267580</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Mi</surname><given-names>LZ</given-names></name><name><surname>Grey</surname><given-names>MJ</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Graef</surname><given-names>E</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><name><surname>Springer</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor</article-title><source>Molecular and Cellular Biology</source><volume>30</volume><fpage>5432</fpage><lpage>5443</lpage><pub-id pub-id-type="doi">10.1128/MCB.00742-10</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luttrell</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Minireview: more than just a hammer: ligand “bias” and pharmaceutical discovery</article-title><source>Molecular Endocrinology</source><volume>28</volume><fpage>281</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1210/me.2013-1314</pub-id><pub-id pub-id-type="pmid">24433041</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>FV</given-names></name><name><surname>Martin</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Deciphering skeletal patterning: clues from the limb</article-title><source>Nature</source><volume>423</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1038/nature01655</pub-id><pub-id pub-id-type="pmid">12748649</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariani</surname><given-names>FV</given-names></name><name><surname>Ahn</surname><given-names>CP</given-names></name><name><surname>Martin</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Genetic evidence that FGFs have an instructive role in limb proximal-distal patterning</article-title><source>Nature</source><volume>453</volume><fpage>401</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/nature06876</pub-id><pub-id pub-id-type="pmid">18449196</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>M</given-names></name><name><surname>Kitoh</surname><given-names>H</given-names></name><name><surname>Ohkawara</surname><given-names>B</given-names></name><name><surname>Mishima</surname><given-names>K</given-names></name><name><surname>Kaneko</surname><given-names>H</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Masuda</surname><given-names>A</given-names></name><name><surname>Ishiguro</surname><given-names>N</given-names></name><name><surname>Ohno</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e81569</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0081569</pub-id><pub-id pub-id-type="pmid">24324705</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Olsen</surname><given-names>SK</given-names></name><name><surname>Ibrahimi</surname><given-names>OA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Structural basis for fibroblast growth factor receptor activation</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>16</volume><fpage>107</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2005.01.008</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moscatelli</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of A role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells</article-title><source>Journal of Cellular Physiology</source><volume>131</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1002/jcp.1041310118</pub-id><pub-id pub-id-type="pmid">3032990</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Needham</surname><given-names>SR</given-names></name><name><surname>Roberts</surname><given-names>SK</given-names></name><name><surname>Arkhipov</surname><given-names>A</given-names></name><name><surname>Mysore</surname><given-names>VP</given-names></name><name><surname>Tynan</surname><given-names>CJ</given-names></name><name><surname>Zanetti-Domingues</surname><given-names>LC</given-names></name><name><surname>Kim</surname><given-names>ET</given-names></name><name><surname>Losasso</surname><given-names>V</given-names></name><name><surname>Korovesis</surname><given-names>D</given-names></name><name><surname>Hirsch</surname><given-names>M</given-names></name><name><surname>Rolfe</surname><given-names>DJ</given-names></name><name><surname>Clarke</surname><given-names>DT</given-names></name><name><surname>Winn</surname><given-names>MD</given-names></name><name><surname>Lajevardipour</surname><given-names>A</given-names></name><name><surname>Clayton</surname><given-names>AHA</given-names></name><name><surname>Pike</surname><given-names>LJ</given-names></name><name><surname>Perani</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>PJ</given-names></name><name><surname>Shan</surname><given-names>Y</given-names></name><name><surname>Shaw</surname><given-names>DE</given-names></name><name><surname>Martin-Fernandez</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>EGFR oligomerization organizes kinase-active dimers into competent signalling platforms</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>13307</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms13307</pub-id><pub-id pub-id-type="pmid">27796308</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolov</surname><given-names>DB</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Himanen</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Homotypic receptor-receptor interactions regulating Eph signaling</article-title><source>Cell Adhesion &amp; Migration</source><volume>8</volume><fpage>360</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.4161/19336918.2014.971684</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>SH</given-names></name><name><surname>Guy</surname><given-names>GR</given-names></name><name><surname>Hadari</surname><given-names>YR</given-names></name><name><surname>Laks</surname><given-names>S</given-names></name><name><surname>Gotoh</surname><given-names>N</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name><name><surname>Lax</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>979</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.3.979-989.2000</pub-id><pub-id pub-id-type="pmid">10629055</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ornitz</surname><given-names>DM</given-names></name><name><surname>Xu</surname><given-names>JS</given-names></name><name><surname>Colvin</surname><given-names>JS</given-names></name><name><surname>McEwen</surname><given-names>DG</given-names></name><name><surname>MacArthur</surname><given-names>CA</given-names></name><name><surname>Coulier</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>GX</given-names></name><name><surname>Goldfarb</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Receptor specificity of the fibroblast growth factor family</article-title><source>The Journal of Biological Chemistry</source><volume>271</volume><fpage>15292</fpage><lpage>15297</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.25.15292</pub-id><pub-id pub-id-type="pmid">8663044</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ornitz</surname><given-names>DM</given-names></name><name><surname>Itoh</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Fibroblast growth factors</article-title><source>Genome Biology</source><volume>2</volume><elocation-id>REVIEWS3005</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2001-2-3-reviews3005</pub-id><pub-id pub-id-type="pmid">11276432</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passos-Bueno</surname><given-names>MR</given-names></name><name><surname>Sertié</surname><given-names>AL</given-names></name><name><surname>Richieri-Costa</surname><given-names>A</given-names></name><name><surname>Alonso</surname><given-names>LG</given-names></name><name><surname>Zatz</surname><given-names>M</given-names></name><name><surname>Alonso</surname><given-names>N</given-names></name><name><surname>Brunoni</surname><given-names>D</given-names></name><name><surname>Ribeiro</surname><given-names>SF</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Description of a new mutation and characterization of FGFR1, FGFR2, and FGFR3 mutations among Brazilian patients with syndromic craniosynostoses</article-title><source>American Journal of Medical Genetics</source><volume>78</volume><fpage>237</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">9677057</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>MD</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The RTK interactome: overview and perspective on RTK heterointeractions</article-title><source>Chemical Reviews</source><volume>119</volume><fpage>5881</fpage><lpage>5921</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.8b00467</pub-id><pub-id pub-id-type="pmid">30589534</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>MD</given-names></name><name><surname>Grubb</surname><given-names>HN</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: implications for cell signaling</article-title><source>Journal of Biological Chemistry</source><volume>295</volume><fpage>9917</fpage><lpage>9933</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.013639</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>MD</given-names></name><name><surname>Rainwater</surname><given-names>R</given-names></name><name><surname>Zuo</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Probing membrane protein association using concentration-dependent number and brightness</article-title><source>Angewandte Chemie</source><volume>60</volume><fpage>6503</fpage><lpage>6508</lpage><pub-id pub-id-type="doi">10.1002/anie.202010049</pub-id><pub-id pub-id-type="pmid">33351993</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priore</surname><given-names>R</given-names></name><name><surname>Dailey</surname><given-names>L</given-names></name><name><surname>Basilico</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Downregulation of Akt activity contributes to the growth arrest induced by FGF in chondrocytes</article-title><source>Journal of Cellular Physiology</source><volume>207</volume><fpage>800</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1002/jcp.20620</pub-id><pub-id pub-id-type="pmid">16523491</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajagopal</surname><given-names>S</given-names></name><name><surname>Ahn</surname><given-names>S</given-names></name><name><surname>Rominger</surname><given-names>DH</given-names></name><name><surname>Gowen-MacDonald</surname><given-names>W</given-names></name><name><surname>Lam</surname><given-names>CM</given-names></name><name><surname>Dewire</surname><given-names>SM</given-names></name><name><surname>Violin</surname><given-names>JD</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Quantifying ligand bias at seven-transmembrane receptors</article-title><source>Molecular Pharmacology</source><volume>80</volume><fpage>367</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1124/mol.111.072801</pub-id><pub-id pub-id-type="pmid">21610196</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raucci</surname><given-names>A</given-names></name><name><surname>Laplantine</surname><given-names>E</given-names></name><name><surname>Mansukhani</surname><given-names>A</given-names></name><name><surname>Basilico</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Activation of the ERK1/2 and p38 mitogen-activated protein kinase pathways mediates fibroblast growth factor-induced growth arrest of chondrocytes</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>1747</fpage><lpage>1756</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310384200</pub-id><pub-id pub-id-type="pmid">14593093</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>C</given-names></name><name><surname>Farge</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Endocytosis switch controlled by transmembrane osmotic pressure and phospholipid number asymmetry</article-title><source>Biophysical Journal</source><volume>78</volume><fpage>3036</fpage><lpage>3047</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(00)76842-1</pub-id><pub-id pub-id-type="pmid">10827982</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>SC</given-names></name><name><surname>Tynan</surname><given-names>JA</given-names></name><name><surname>Donoghue</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>RTK mutations and human syndromeswhen good receptors turn bad</article-title><source>Trends in Genetics</source><volume>16</volume><fpage>265</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/s0168-9525(00)02021-7</pub-id><pub-id pub-id-type="pmid">10827454</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roghani</surname><given-names>M</given-names></name><name><surname>Mansukhani</surname><given-names>A</given-names></name><name><surname>Dell’Era</surname><given-names>P</given-names></name><name><surname>Bellosta</surname><given-names>P</given-names></name><name><surname>Basilico</surname><given-names>C</given-names></name><name><surname>Rifkin</surname><given-names>DB</given-names></name><name><surname>Moscatelli</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>3976</fpage><lpage>3984</lpage><pub-id pub-id-type="pmid">8307953</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Mosonego-Ornan</surname><given-names>E</given-names></name><name><surname>Sadot</surname><given-names>E</given-names></name><name><surname>Madar-Shapiro</surname><given-names>L</given-names></name><name><surname>Sheinin</surname><given-names>Y</given-names></name><name><surname>Ginsberg</surname><given-names>D</given-names></name><name><surname>Yayon</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Induction of chondrocyte growth arrest by FGF: transcriptional and cytoskeletal alterations</article-title><source>Journal of Cell Science</source><volume>115</volume><fpage>553</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1242/jcs.115.3.553</pub-id><pub-id pub-id-type="pmid">11861762</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarabipour</surname><given-names>S</given-names></name><name><surname>Del Piccolo</surname><given-names>N</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Characterization of membrane protein interactions in plasma membrane derived vesicles with quantitative imaging förster resonance energy transfer</article-title><source>Accounts of Chemical Research</source><volume>48</volume><fpage>2262</fpage><lpage>2269</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.5b00238</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarabipour</surname><given-names>S</given-names></name><name><surname>Ballmer-Hofer</surname><given-names>K</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>VEGFR-2 conformational switch in response to ligand binding</article-title><source>eLife</source><volume>5</volume><elocation-id>e13876</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.13876</pub-id><pub-id pub-id-type="pmid">27052508</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarabipour</surname><given-names>S</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanism of FGF receptor dimerization and activation</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10262</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10262</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheck</surname><given-names>RA</given-names></name><name><surname>Lowder</surname><given-names>MA</given-names></name><name><surname>Appelbaum</surname><given-names>JS</given-names></name><name><surname>Schepartz</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Bipartite tetracysteine display reveals allosteric control of ligand-specific EGFR activation</article-title><source>ACS Chemical Biology</source><volume>7</volume><fpage>1367</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1021/cb300216f</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Cell Signaling by receptor tyrosine kinases</article-title><source>Cell</source><volume>103</volume><fpage>211</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)00114-8</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Common and distinct elements in cellular signaling via EGF and FGF receptors</article-title><source>Science</source><volume>306</volume><fpage>1506</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1126/science.1105396</pub-id><pub-id pub-id-type="pmid">15567848</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seiradake</surname><given-names>E</given-names></name><name><surname>Harlos</surname><given-names>K</given-names></name><name><surname>Sutton</surname><given-names>G</given-names></name><name><surname>Aricescu</surname><given-names>AR</given-names></name><name><surname>Jones</surname><given-names>EY</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>17</volume><fpage>398</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1782</pub-id><pub-id pub-id-type="pmid">20228801</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seiradake</surname><given-names>E</given-names></name><name><surname>Schaupp</surname><given-names>A</given-names></name><name><surname>del Toro Ruiz</surname><given-names>D</given-names></name><name><surname>Kaufmann</surname><given-names>R</given-names></name><name><surname>Mitakidis</surname><given-names>N</given-names></name><name><surname>Harlos</surname><given-names>K</given-names></name><name><surname>Aricescu</surname><given-names>AR</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>EY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structurally encoded intraclass differences in EphA clusters drive distinct cell responses</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>20</volume><fpage>958</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2617</pub-id><pub-id pub-id-type="pmid">23812375</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>AN</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Sun</surname><given-names>PL</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Jheon</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>CT</given-names></name><name><surname>Chung</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer</article-title><source>Virchows Archiv</source><volume>465</volume><fpage>547</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1007/s00428-014-1634-2</pub-id><pub-id pub-id-type="pmid">25086725</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>DR</given-names></name><name><surname>Kanvinde</surname><given-names>P</given-names></name><name><surname>King</surname><given-names>C</given-names></name><name><surname>Pasquale</surname><given-names>EB</given-names></name><name><surname>Hristova</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures</article-title><source>Communications Biology</source><volume>1</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-018-0017-7</pub-id><pub-id pub-id-type="pmid">30271902</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>B</given-names></name><name><surname>Köster</surname><given-names>D</given-names></name><name><surname>Ruez</surname><given-names>R</given-names></name><name><surname>Gonnord</surname><given-names>P</given-names></name><name><surname>Bastiani</surname><given-names>M</given-names></name><name><surname>Abankwa</surname><given-names>D</given-names></name><name><surname>Stan</surname><given-names>RV</given-names></name><name><surname>Butler-Browne</surname><given-names>G</given-names></name><name><surname>Vedie</surname><given-names>B</given-names></name><name><surname>Johannes</surname><given-names>L</given-names></name><name><surname>Morone</surname><given-names>N</given-names></name><name><surname>Parton</surname><given-names>RG</given-names></name><name><surname>Raposo</surname><given-names>G</given-names></name><name><surname>Sens</surname><given-names>P</given-names></name><name><surname>Lamaze</surname><given-names>C</given-names></name><name><surname>Nassoy</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cells respond to mechanical stress by rapid disassembly of caveolae</article-title><source>Cell</source><volume>144</volume><fpage>402</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.12.031</pub-id><pub-id pub-id-type="pmid">21295700</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>JS</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name><name><surname>Rajagopal</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Biased signalling: from simple switches to allosteric microprocessors</article-title><source>Nature Reviews. Drug Discovery</source><volume>17</volume><fpage>243</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.229</pub-id><pub-id pub-id-type="pmid">29302067</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorokin</surname><given-names>A</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Internalization of fibroblast growth factor receptor is inhibited by a point mutation at tyrosine 766</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>17056</fpage><lpage>17061</lpage><pub-id pub-id-type="pmid">7516330</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoneman</surname><given-names>MR</given-names></name><name><surname>Biener</surname><given-names>G</given-names></name><name><surname>Ward</surname><given-names>RJ</given-names></name><name><surname>Pediani</surname><given-names>JD</given-names></name><name><surname>Badu</surname><given-names>D</given-names></name><name><surname>Eis</surname><given-names>A</given-names></name><name><surname>Popa</surname><given-names>I</given-names></name><name><surname>Milligan</surname><given-names>G</given-names></name><name><surname>Raicu</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A general method to quantify ligand-driven oligomerization from fluorescence-based images</article-title><source>Nature Methods</source><volume>16</volume><fpage>493</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0408-9</pub-id><pub-id pub-id-type="pmid">31110281</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suwanmajo</surname><given-names>T</given-names></name><name><surname>Krishnan</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Biphasic responses in multi-site phosphorylation systems</article-title><source>Journal of the Royal Society, Interface</source><volume>10</volume><elocation-id>20130742</elocation-id><pub-id pub-id-type="doi">10.1098/rsif.2013.0742</pub-id><pub-id pub-id-type="pmid">24108693</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabin</surname><given-names>C</given-names></name><name><surname>Wolpert</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Rethinking the proximodistal axis of the vertebrate limb in the molecular era</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>1433</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1101/gad.1547407</pub-id><pub-id pub-id-type="pmid">17575045</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>DC</given-names></name><name><surname>Lamont</surname><given-names>FR</given-names></name><name><surname>Shnyder</surname><given-names>SD</given-names></name><name><surname>Knowles</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer</article-title><source>Cancer Research</source><volume>69</volume><fpage>4613</fpage><lpage>4620</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2816</pub-id><pub-id pub-id-type="pmid">19458078</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Pearson</surname><given-names>A</given-names></name><name><surname>Sharpe</surname><given-names>R</given-names></name><name><surname>Lambros</surname><given-names>M</given-names></name><name><surname>Geyer</surname><given-names>F</given-names></name><name><surname>Lopez-Garcia</surname><given-names>MA</given-names></name><name><surname>Natrajan</surname><given-names>R</given-names></name><name><surname>Marchio</surname><given-names>C</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Mackay</surname><given-names>A</given-names></name><name><surname>Gillett</surname><given-names>C</given-names></name><name><surname>Grigoriadis</surname><given-names>A</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer</article-title><source>Cancer Research</source><volume>70</volume><fpage>2085</fpage><lpage>2094</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3746</pub-id><pub-id pub-id-type="pmid">20179196</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wacker</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Katritch</surname><given-names>V</given-names></name><name><surname>Han</surname><given-names>GW</given-names></name><name><surname>Huang</surname><given-names>XP</given-names></name><name><surname>Vardy</surname><given-names>E</given-names></name><name><surname>McCorvy</surname><given-names>JD</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Chu</surname><given-names>M</given-names></name><name><surname>Siu</surname><given-names>FY</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>HE</given-names></name><name><surname>Cherezov</surname><given-names>V</given-names></name><name><surname>Roth</surname><given-names>BL</given-names></name><name><surname>Stevens</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural features for functional selectivity at serotonin receptors</article-title><source>Science</source><volume>340</volume><fpage>615</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1126/science.1232808</pub-id><pub-id pub-id-type="pmid">23519215</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendt</surname><given-names>DJ</given-names></name><name><surname>Dvorak-Ewell</surname><given-names>M</given-names></name><name><surname>Bullens</surname><given-names>S</given-names></name><name><surname>Lorget</surname><given-names>F</given-names></name><name><surname>Bell</surname><given-names>SM</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Castillo</surname><given-names>S</given-names></name><name><surname>Aoyagi-Scharber</surname><given-names>M</given-names></name><name><surname>O’Neill</surname><given-names>CA</given-names></name><name><surname>Krejci</surname><given-names>P</given-names></name><name><surname>Wilcox</surname><given-names>WR</given-names></name><name><surname>Rimoin</surname><given-names>DL</given-names></name><name><surname>Bunting</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>353</volume><fpage>132</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1124/jpet.114.218560</pub-id><pub-id pub-id-type="pmid">25650377</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>KE</given-names></name><name><surname>Cabral</surname><given-names>JM</given-names></name><name><surname>Davis</surname><given-names>SI</given-names></name><name><surname>Fishburn</surname><given-names>T</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Ichikawa</surname><given-names>S</given-names></name><name><surname>Fields</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Shaw</surname><given-names>NJ</given-names></name><name><surname>McLellan</surname><given-names>NJ</given-names></name><name><surname>McKeown</surname><given-names>C</given-names></name><name><surname>Fitzpatrick</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Ornitz</surname><given-names>DM</given-names></name><name><surname>Econs</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation</article-title><source>American Journal of Human Genetics</source><volume>76</volume><fpage>361</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1086/427956</pub-id><pub-id pub-id-type="pmid">15625620</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkie</surname><given-names>AOM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>16</volume><fpage>187</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2005.03.001</pub-id><pub-id pub-id-type="pmid">15863034</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wykosky</surname><given-names>J</given-names></name><name><surname>Palma</surname><given-names>E</given-names></name><name><surname>Gibo</surname><given-names>DM</given-names></name><name><surname>Ringler</surname><given-names>S</given-names></name><name><surname>Turner</surname><given-names>CP</given-names></name><name><surname>Debinski</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Soluble monomeric EphrinA1 is released from tumor cells and is a functional ligand for the EphA2 receptor</article-title><source>Oncogene</source><volume>27</volume><fpage>7260</fpage><lpage>7273</lpage><pub-id pub-id-type="doi">10.1038/onc.2008.328</pub-id><pub-id pub-id-type="pmid">18794797</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xian</surname><given-names>W</given-names></name><name><surname>Schwertfeger</surname><given-names>KL</given-names></name><name><surname>Rosen</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Distinct roles of fibroblast growth factor receptor 1 and 2 in regulating cell survival and epithelial-mesenchymal transition</article-title><source>Molecular Endocrinology</source><volume>21</volume><fpage>987</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1210/me.2006-0518</pub-id><pub-id pub-id-type="pmid">17284663</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>Q</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>JQ</given-names></name><name><surname>Qi</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>FGF/FGFR signaling in health and disease</article-title><source>Signal Transduction and Targeted Therapy</source><volume>5</volume><elocation-id>181</elocation-id><pub-id pub-id-type="doi">10.1038/s41392-020-00222-7</pub-id><pub-id pub-id-type="pmid">32879300</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J-L</given-names></name><name><surname>Huang</surname><given-names>Z-F</given-names></name><name><surname>Yin</surname><given-names>J-Q</given-names></name><name><surname>Deng</surname><given-names>Y-L</given-names></name><name><surname>Xie</surname><given-names>X-B</given-names></name><name><surname>Li</surname><given-names>F-B</given-names></name><name><surname>Yang</surname><given-names>J-F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A proposed classification system for guiding surgical strategy in cases of severe spinal deformity based on spinal cord function</article-title><source>European Spine Journal</source><volume>25</volume><fpage>1821</fpage><lpage>1829</lpage><pub-id pub-id-type="doi">10.1007/s00586-015-4367-2</pub-id><pub-id pub-id-type="pmid">26769035</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XQ</given-names></name><name><surname>Ibrahimi</surname><given-names>OA</given-names></name><name><surname>Olsen</surname><given-names>SK</given-names></name><name><surname>Umemori</surname><given-names>H</given-names></name><name><surname>Mohammadi</surname><given-names>M</given-names></name><name><surname>Ornitz</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>15694</fpage><lpage>15700</lpage><pub-id pub-id-type="doi">10.1074/jbc.M601252200</pub-id><pub-id pub-id-type="pmid">16597617</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>GW</given-names></name><name><surname>Abagyan</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Stevens</surname><given-names>RC</given-names></name><name><surname>Cherezov</surname><given-names>V</given-names></name><name><surname>Kufareva</surname><given-names>I</given-names></name><name><surname>Handel</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV</article-title><source>Immunity</source><volume>46</volume><fpage>1005</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.05.002</pub-id><pub-id pub-id-type="pmid">28636951</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88144.4.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Goethe University</institution><country>Germany</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Solid</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Useful</kwd></kwd-group></front-stub><body><p>This manuscript describes <bold>useful</bold> data on the mechanisms underlying the activation of the receptor tyrosine kinase FGFR1 and stimulation of intracellular signaling pathways in response to FGF4, FGF8, or FGF9 binding to the extracellular domain of FGFR1. <bold>Solid</bold> evidence for quantitative differences in the downstream responses induced by the three ligands is presented. This manuscript will be of interest to biochemists and cell biologists working on receptor tyrosine kinases and general cell signalling across membranes.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88144.4.sa1</article-id><title-group><article-title>Joint Public Review:</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In this manuscript, Karl et al. explore mechanisms underlying the activation of the receptor tyrosine kinase FGFR1 and stimulation of intracellular signaling pathways in response to FGF4, FGF8, or FGF9 binding to the extracellular domain of FGFR1. The manuscript demonstrates that FGF4, FGF8, and FGF9 exhibit distinct binding modes towards FGFRs. It is also proposed that FGF8 exhibits &quot;biased ligand&quot; characteristics that is manifested via binding and activation FGFR1 mediated by unproven and speculative &quot;structural differences in the FGF-FGFR1 dimers, which impact the interactions of the FGFR1 trans membrane helices, leading to differential recruitment and activation of the downstream signaling adapter FRS2&quot;.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88144.4.sa2</article-id><title-group><article-title>Author Response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Karl</surname><given-names>Kelly</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Del Piccolo</surname><given-names>Nuala</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Light</surname><given-names>Taylor</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Roy</surname><given-names>Tanaya</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Deduja</surname><given-names>Pooja</given-names></name><role specific-use="author">Author</role><aff><institution>Masaryk University</institution><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Ursachi</surname><given-names>Vlad</given-names></name><role specific-use="author">Author</role><aff><institution>Masaryk University</institution><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Fafilek</surname><given-names>Bohumil</given-names></name><role specific-use="author">Author</role><aff><institution>Masaryk University</institution><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Krejci</surname><given-names>Pavel</given-names></name><role specific-use="author">Author</role><aff><institution>Masaryk University</institution><addr-line><named-content content-type="city">Brno</named-content></addr-line><country>Czech Republic</country></aff></contrib><contrib contrib-type="author"><name><surname>Hristova</surname><given-names>Kalina</given-names></name><role specific-use="author">Author</role><aff><institution>Johns Hopkins University</institution><addr-line><named-content content-type="city">Baltimore</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the current reviews.</p><disp-quote content-type="editor-comment"><p>Comment. “The manuscript demonstrates that FGF4, FGF8, and FGF9 exhibit distinct binding modes towards FGFRs”</p></disp-quote><p>No, this paper is not about ligand binding, and there are NO binding data in the manuscript. This paper is about ligand-dependent functional bias. Previously, differential effects of ligands on the signaling of one FGFR have been attributed to differences in ligand binding, but that paradigm is incomplete, if not incorrect. This manuscript is the first demonstration that three FGF ligands induce bias in FGFR1 signaling. FGF8 preferentially activates some of the probed downstream responses (FRS2 phosphorylation and extracellular matrix loss), while FGF4 and FGF9 preferentially activate different probed responses (FGFR1 phosphorylation and growth arrest). The bias we report here cannot be the result of differences in ligand binding. Indeed, if the differences between ligands are only in the binding strength, then a strongly binding ligand at low concentration will act identically to weakly binding ligand at high concentration. Our article thus changes the current paradigm about how FGF ligands activate FGFR signaling.</p><disp-quote content-type="editor-comment"><p>Comment. It is also proposed that FGF8 exhibits &quot;biased ligand&quot; characteristics.</p></disp-quote><p>We do not “propose” the existence of ligand bias, we demonstrate it in the manuscript by following the latest IUPHAR community guidelines on bias identification and quantification (Kolb et al, 2022). We calculate bias coefficients, and we analyze the results using statistical tools.</p><disp-quote content-type="editor-comment"><p>Comment. …“Unproven and speculative structural differences in the FGF-FGFR1 dimers”.</p></disp-quote><p>This statement is not correct, as it is directly contradicted by the differences reported in Figure 6. This Figure presents the results of a quantitative FRET assay performed at high ligand concentration, which ensures that there are no monomeric receptors. Under these conditions, the measured FRET efficiency depends only on the dimer conformation. The measured differences in FRET efficiencies reveal distinct differences in the FGFR1 TM domain dimer conformations when FGF8 is bound to the extracellular domain of FGFR1, as compared to FGF4 and FGF9. The difference can be observed in the raw FRET data in Figure 6A. While these data do not reveal the exact molecular origin of the structural differences, they unequivocally prove that there are structural differences when different ligands are bound.</p><p>References</p><p>Kolb P, Kenakin T, Alexander SPH, Bermudez M, et al. Community guidelines for GPCR ligand bias: IUPHAR review 32. Br J Pharmacol. 2022;179, 3651-3674.</p><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p>eLife assessment. This manuscript describes useful data on the mechanisms underlying the activation of the receptor tyrosine kinase FGFR1 and stimulation of intracellular signaling pathways in response to FGF4, FGF8, or FGF9 binding to the extracellular domain of FGFR1. Solid quantitative binding experiments are presented to demonstrate that FGF4, FGF8, and FGF9 exhibit distinct binding affinities towards FGFRs.</p></disp-quote><p>No, this paper is not about binding, and there is NO binding data in the manuscript. This paper is about function. This is the first demonstration that three FGF ligands induce bias in FGFR1 signaling. Thus far, differential effects in the signaling of one FGFR have been attributed to differences in ligand binding, but this current paradigm is incomplete/incorrect. Our article changes the current paradigm in how FGF activate downstream FGFR signaling.</p><p>We have clarified this point by adding the following text in the Discussion.</p><p>&quot;Thus far, differential effects in the signaling of one FGFR in response to different FGF ligands have been attributed to differences in ligand binding. It can be reasoned, however, that differences in ligand binding strengths, alone, cannot explain differential signaling. Indeed, if the differences between ligands are only in the binding strength, then a strongly binding ligand at low concentration will act identically to weakly binding ligand at high concentration. Here we discovered, using tools that are novel for the RTK field, that there are qualitative differences in the actions of the ligands. FGF8 preferentially activates some of the probed downstream responses (FRS2 phosphorylation and collagen loss), while FGF4 and FGF9 preferentially activate different probed responses (FGFR1 phosphorylation and growth arrest). These effects occur in addition to previously measured differences in ligand binding coefficients (87).”</p><p>We have also re-written the abstract.</p><p>“Abstract</p><p>“The mechanism of differential signaling of multiple FGF ligands through a single FGF receptor is poorly understood. Here, we use biophysical tools to quantify multiple aspects of FGFR1 signaling in response to FGF4, FGF8 and FGF9: potency, efficacy, bias, ligand-induced oligomerization and downregulation, and conformation of the active FGFR1 dimers. We find that the three ligands exhibit distinctly different potencies and efficacies for inducing responses in cells. We further discover qualitative differences in the actions of the three FGFs through FGFR1, as FGF8 preferentially activates some of the probed downstream responses (FRS2 phosphorylation and extracellular matrix loss), while FGF4 and FGF9 preferentially activate different probed responses (FGFR1 phosphorylation and cell growth arrest). Thus, FGF8 is a biased ligand, when compared to FGF4 and FGF9. Förster resonance energy transfer experiments reveal a correlation between biased signaling and the conformation of the FGFR1 transmembrane domain dimer. Our findings expand the mechanistic understanding of FGF signaling during development and bring the poorly understood concept of receptor tyrosine kinase ligand bias into the spotlight.”</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Comment. Quantitative binding experiments presented in the manuscript demonstrate that FGF4, FGF8, and FGF9 exhibit distinct binding affinities towards FGFRs.</p></disp-quote><p>This paper is not about binding, and there is NO binding data in the manuscript. This paper is about function. Please see our response to the Elife assessment.</p><disp-quote content-type="editor-comment"><p>Comment. It is also proposed that FGF8 exhibits &quot;biased ligand&quot; characteristics that is manifested via binding and activation FGFR1 mediated by &quot;structural differences in the FGF- FGFR1 dimers, which impact the interactions of the FGFR1 transmembrane helices, leading to differential recruitment and activation of the downstream signaling adapter FRS2&quot;.</p></disp-quote><p>We do not “propose” the existence of ligand bias, we demonstrate it in the manuscript by following the latest IUPHAR community guidelines on bias identification and quantification (Kolb et al, 2022). Specifically, we construct bias plots, we calculate bias coefficients, and we analyze the results using statistical tools.</p><p>Also, please note that ligand bias has no direct connection to binding strength, so the statement that biased ligand characteristics “is manifested via binding” is not correct.</p><disp-quote content-type="editor-comment"><p>Comment. In the absence of any structural experimental data of different forms of FGFR dimers stimulated by FGF ligands the model presents in the manuscript is speculative and misleading.</p></disp-quote><p>Figure 6 presents the “structural experimental data”. A quantitative FRET assay is performed at high ligand concentration, which ensures that there are no monomeric receptors. Under these conditions, the measured FRET efficiency depends only on the dimer conformation. The measured FRET efficiencies reveal distinct differences in the FGFR1 TM domain dimer conformations when the ligand FGF8 is bound to the extracellular domain of FGFR1, as compared to the cases of FGF4 and FGF8.</p><p>Because the Rosetta modeling of the kinase domains in the previous version of the paper is not based on experimental data, we have removed the modeling from the Results, and we have removed all references to it in the Discussion. Thus, all that is shown and discussed in the revised paper is based on experimental data.</p><p>We have substituted two paragraphs in the discussion with the following two sentences:</p><p>“The experimental data in Figure 6 hint at the possibility that ligand bias arises due to differences in FGFR1 dimer conformations. If this is so, then conformational differences in the signaling complex in the plasma membrane underlie biased signaling for both RTKs and GPCRs, the two largest receptor families in the human genome”.</p><p>References</p><p>Kolb P, Kenakin T, Alexander SPH, Bermudez M, et al. Community guidelines for GPCR ligand bias: IUPHAR review 32. Br J Pharmacol. 2022;179, 3651-3674.</p></body></sub-article></article>